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Buccal delivery of antiretroviral (ARV) drugs may overcome disadvantages such as low 
bioavailability due to extensive first pass effects and gastrointestinal degradation associated 
with the oral route. However, the small mucosal surface area and low membrane permeability 
are challenges to buccal drug permeation. Identification of new permeation enhancers as well 
as new permeation enhancing strategies have been shown to overcome these limitations, 
thereby delivering adequate amounts of drug through the buccal mucosa. Polymeric excipients 
with previously reported mucoadhesive and controlled release properties could also possess 
additional buccal permeation enhancing effects and may therefore serve as multifunctional 
excipients in a buccal drug delivery system. Therefore the aims of this study were: 1) to identify 
and compare the buccal permeability potential of tenofovir (TNF) and didanosine (ddI). 2) to 
identify the buccal permeation effects of potential multifunctional excipients ie. 
carboxymethylcellulose (CMC), sodium alginate (SA), polyacrylic acid (PAA) and polyethylene 
glycol (PEG) for TNF and ddI, and 3) to identify the buccal permeation potential of saquinavir 
(SQV) and assess the effect of high-energy ball milling on its permeability.  
  
All in vitro permeation studies across porcine buccal mucosa were performed using vertical 
Franz diffusion cells with TNF, ddI and SQV being quantified using UV spectrophotometry at 
262 nm, 250 nm and 239 nm respectively. The histomorphological evaluations were undertaken 
by light microscopy (LM) and Transmission Electron Microscopy (TEM). Ball milling of SQV 
samples for 1, 3, 15 and 30 hours was performed in a high-energy planetary mill. The integrity 
of the buccal mucosa was assessed by transepithelial electrical resistance (TEER) 
measurements using a Millicell ERS meter connected to a pair of chopstick electrodes. 
 
Both TNF and ddI were able to permeate the buccal mucosa in a concentration-dependent 
manner.  A higher permeability was observed for ddI (Flux = 181.62 ± 23.62 µg/cm2h) as 
compared to TNF (Flux = 102.10 ± 19.80 µg/cm2h). The permeation of these drugs in the 
absence of enhancers was attributed to passive diffusion via the paracellular route with 
transcellular route being an additional possibility for ddI. The addition of PAA, SA, CMC and 
PEG increased the permeability of TNF whilst only PEG was able to increase the permeability of 
ddI. The effect of these polymeric excipients appeared to be dependent on their ionic charges 
as well as that of the respective drugs. Permeability enhancement ratios for ddI and TNF were 
1.63 and 1.74 respectively with PEG (0.5 %w/v) and CMC (0.5 %w/v) respectively. A maximum 
enhancement ratio of 2.13 for TNF was achieved with 4 %w/v PEG. Furthermore PEG was 
identified as the optimal permeation enhancer for TNF and ddI. Histological investigations 
revealed no significant loss in cellular integrity for mucosa treated with either TNF or ddI alone 
or when coupled with PEG as an enhancer. The differences in histomorphological changes in 
response to TNF and ddI alone could support the greater permeation observed with ddI. The 
histological findings proved useful in assessing the effects of drug and enhancer on mucosal 
integrity and provided insight into permeation pathways across the mucosa. Selective polymeric 
excipients therefore provide an effective means to increase the penetration of ddI and TNF. 
Their previously reported mucoadhesive and controlled release properties coupled with their 
permeation enhancing effects shown in this study highlight their potential use as multifunctional 
excipients for the design of buccal drug delivery systems. 
  
SQV, a candidate for buccal drug delivery, is limited by its poor solubility. Therefore, Aim 3 
identified the effects of high energy ball milling on the buccal permeability of SQV and compared 
it’s enhancing effect to the conventional use of common chemical enhancers together with 
unmilled SQV i.e. ethylenediaminetetraacetic acid (EDTA), sodium lauryl sulphate (SLS), PEG 
ii 
 
and beta cyclodextrin (ß-cyclodextrin). Unmilled SQV was able to permeate through the buccal 
mucosa with a flux of 3.99 ± 0.11µg/cm2h. Ball milling of SQV at all the time periods led to an 
increase in its permeability with optimal enhancement obtained at 15 hours with an 
enhancement ratio of 2.61. The enhanced permeability of the milled SQV samples was 
attributed to a contribution of various factors such as solubility, particle size, surface area, 
crystallinity, morphology and the formation of solid dispersions. The chemical permeation 
enhancers were also able to increase the permeability of unmilled SQV across the buccal 
mucosa, with SLS achieving the greatest enhancement ratio of 1.75. However, ball milling of 
SQV without any chemical permeation enhancers displayed to a greater enhancement ratio 
(2.61) as compared to the best permeation enhancer SLS at 0.5 %w/v (1.75). Histological 
investigations revealed no significant loss in cellular integrity for mucosa treated with either 
unmilled or milled SQV samples. The presence of larger intercellular spaces in the treated 
tissue suggests that SQV also uses the paracellular route of transport in combination with the 
transcellular route across the mucosa. High energy ball milling of SQV is therefore an effective 
approach for increasing buccal permeability when formulating SQV for a buccal delivery system, 
as compared to incorporating common chemical enhancers studied at 0.5% w/v for this 
purpose. 
 
The findings in this study will therefore contribute to formulation optimization strategies for the 
development of novel buccal delivery systems for ARV drugs, thereby optimising treatment of 
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CHAPTER 1 - INTRODUCTION 
 
1.1 INTRODUCTION 
This chapter describes the background and rationale for this study, outlining the challenges 
encountered with current antiretroviral therapy and the approaches to overcome these 
limitations. The significance and the novelty of the study are also outlined. This chapter is 
concluded with the overview of this dissertation.   
 
1.2 BACKGROUND TO THIS STUDY 
Oral antiretroviral (ARV) drug therapy has significantly improved the treatment of human 
immunodeficiency virus (HIV) infection and acquired immune deficiency syndrome (AIDS), 
which are considered among the most serious public health diseases (1,2) in South Africa. With 
current statistics indicating that more than 2.3 million new infections worldwide were recorded in 
2012, it is evident that the prevalence of the disease is still high. This is also the case in sub-
Saharan Africa, where there are currently more than 25 million people living with HIV (3). With 
no cure for HIV or an effective vaccine, ARVs are the only treatment available to patients living 
with HIV.  The benefits of current treatment are a reduced risk of progression to AIDS and a 
decreased risk of early death. Treatment reduces the risk of acquiring opportunistic infections 
such as tuberculosis and also improves mental and physical health.  
 
Additional benefits include reduced mother-to-child transmission and also a decreased risk of 
transmission of the disease to sexual partners (4). The effectiveness of treatment depends on 
patient compliance, the complexity of treatment regimens (due to pills burden and dosing 
frequency) and adverse effects, which may reduce patient adherence (4). Some ARV drugs 
have low bioavailabilities due to extensive gastrointestinal degradation and first pass 




metabolism, and have short half-lives, requiring frequent drug administration. Their frequent 
administration leads to severe dose-dependent side-effects, which further exacerbate the 
decrease in patient compliance (5).  All these limitations i.e. decreased patient compliance, low 
bioavailability and short half-lives of many of these ARV drugs, negatively impact on the 
effective treatment of HIV and AIDS. Successful treatment largely depends on the ARV plasma 
concentration being relatively high in order to completely suppress viral replication (6). 
 
In order to address these limitations of ARV treatment, formulation scientists have been 
exploring the use of novel drug delivery systems and alternate routes of drug administration (5). 
Alternate routes of drug administration that obviate the gastrointestinal tract as well as hepatic 
first pass metabolism and deliver drug directly into the systemic circulation will be beneficial to 
many ARVs that are susceptible to the above mentioned limitations. Therefore, there has been 
much interest in the use of the mucosal lining of body cavities as alternative routes of drug 
administration (7). Potential sites for this type of drug delivery are: the oral cavity, vaginal, rectal, 
and nasal as well as the ocular route. The oral cavity comprises of three different categories of 
drug delivery i.e. sublingual, buccal and local drug delivery (8). These oral mucosal sites differ 
significantly from each other in terms of structure, the ability to retain a delivery system as well 
as permeability.  
 
Compared to the skin for transdermal delivery, the permeability of the buccal mucosa is higher, 
cell recovery is more rapid, and it has easier access than nasal, rectal and vaginal mucosa (9). 
The buccal mucosa is also more resistant to irritation, and has greater patient acceptability than 
other non-oral routes. The buccal mucosa is more suited for sustained/controlled release 
dosage forms than the rest of the oral mucosa. This route is also advantageous for paediatrics 
and patients with swallowing problems. The buccal mucosa therefore presents as an attractive 




site for ARV drug delivery (10, 11). While ARV drugs have been more widely studied for their 
transdermal route of administration (12-15), research on their buccal permeability properties 
appear to be limited. The literature indicates that only Didanosine and Zalcitabine have been 
studied for their buccal permeation properties (16, 17), necessitating further studies on 
optimizing their delivery via this route.   
 
The advantages of the buccal route has led to the design and evaluation of various buccal 
delivery systems, such as wafers, films, patches, tablets, pastes and gels (12). However, one of 
the main disadvantages of the buccal route is the low mucosal permeability, necessitating the 
use of various classes of permeation enhancers to facilitate drug permeation (18). The 
permeability of drugs from these delivery systems can therefore be improved with the 
incorporation of permeation enhancers into the formulations. Both physical as well as chemical 
methods have been investigated to enhance the permeation of drugs across the buccal 
mucosa. Chemical permeation enhancers are most widely studied for the buccal route (18). 
There are several classes of chemical permeation enhancers, including surfactants, fatty acids, 
bile salts, inclusion complexes, chelators, and polymers (19). These enhancers alter mucosal 
permeability by various mechanisms that decrease the barrier properties of either the mucosal 
surface, or the transport pathways across the mucosa.  
 
In order to facilitate prolonged retention of the formulation on the mucosa allowing for sustained 
delivery and permeation, buccal delivery systems also need to display mucoadhesivity, i.e. they 
need to adhere to the mucus layer covering the buccal mucosa. To meet the challenges of 
buccal delivery, the key properties needed for a buccal drug delivery system are drug 
permeation enhancement, mucoadhesivity and controlled drug release. The identification of 
formulation excipients to provide these properties is therefore critical. Various polymers, such as 




cellulose derivatives, and those based on polymethacrylic acid, polysaccharides and alginic 
acid, have successfully shown mucoadhesive and sustained drug release properties (20). 
 
The identification of excipients with potential multifunctional properties, such as mucoadhesivity, 
drug permeation enhancement and controlled drug release, will significantly contribute to the 
optimization of the design of buccal delivery systems. The multifunctional properties required for 
buccal delivery systems have led investigators to study, different classes of excipients 
separately, as permeation enhancers and polymers that have either or both mucoadhesive and 
controlled release properties. There is a need for the use of multifunctional pharmaceutical 
excipients in the design of buccal delivery systems, i.e. excipients that could simultaneously 
provide mucoadhesivity, sustained drug release and permeation enhancement. The use of 
multifunctional excipients for buccal drug delivery will decrease the number and quantity of 
excipients required in product formulation. The advantages will include decreased 
manufacturing costs, adverse effects, allergic reactions and excipient incompatibilities. 
 
In addition, for drugs that have poorly aqueous solubility, approaches that increase this may 
also prove advantageous for their buccal delivery. Common approaches used to enhance low 
aqueous solubility of drugs include methods that reduce particle size (including microsizing and 
nanosizing), increase their solubilisation in co-solvents, improve their complexation with 
cyclodextrins, or for the delivery of lipophilic drugs, use lipid-based vehicles as well as solid 
dispersion technology (21,22). The success of increasing the solubility of a poorly soluble drug 
is dependent on the physicochemical properties of that drug, although many of these techniques 
have been shown to be effective at enhancing oral bioavailability for specific compounds. Poorly 
soluble drugs, including some poorly soluble ARVs, have been presented in the literature using 
a number of these strategies to enhance their aqueous solubility.  




The formation of amorphous solids or solid dispersions also presents a promising approach to 
overcome limited solubility of poorly soluble drug (23). Although milling is an approach widely 
used to reduce particle size, it is not commonly used for making amorphous dispersions, despite 
being shown to be suitable for this purpose (23). Recent studies have shown that ball milling is 
a viable process for producing amorphous and solid dispersions (24, 25). The advantage of high 
energy ball milling is generating an amorphous system while simultaneously stimulating the 
formation of reduced particle size (26). Using such a technique for a drug with low aqueous 
solubility to improve its solubility could prove to be very beneficial, with regards to its buccal 
permeability potential. This technique could therefore obviate the use of chemical permeation 
enhancers in formulations that incorporate a poorly soluble drug, thus limiting the risks 
associated with the use of chemical enhancers. If successful, this strategy would widen the pool 
of approaches used to enhance permeation across the buccal mucosa. 
 
1.2 AIMS AND OBJECTIVES OF THIS STUDY 
The aims of this study were therefore to: 
1. Identify and compare the buccal permeability potential of tenofovir (TNF) and didanosine 
(ddI). 
2. Identify potential multifunctional excipients as buccal permeation enhancers for TNF and 
ddI.  
3. Identify the buccal permeation potential of saquinavir (SQV), and assess the effect of 
high-energy ball milling on the buccal permeability of SQV. 
 
In order to achieve Aims 1 and 2 the objectives were to: 
 Determine and compare the in vitro buccal permeability parameters for TNF and ddI. 




 Assess the histomorphological effects of TNF and ddI on the buccal mucosa. 
 Determine the effects of poly (acrylic acid) (PAA), sodium alginate (SA), poly(ethylene 
glycol) (PEG) and carboxymethylcellulose (CMC) as possible multifunctional excipients 
on the permeability parameters of TNF and ddI. 
  Determine the concentration effects of the best identified multifunctional excipient on the 
permeability parameters of TNF and ddI, as well as to assess the histomorphological 
effects of this excipient on the buccal mucosa. 
 
In order to achieve Aim 3 the objectives were to: 
 Identify the in vitro buccal permeability parameters of unmilled SQV and ball milled SQV. 
 Compare the permeation enhancement effect of ball milled SQV to common chemical 
enhancers. 
 Assess the histomorphological effects of unmilled SQV and milled SQV samples on the 
buccal mucosa. 
 
1.3 SIGNIFICANCE OF THIS STUDY 
The findings of this study will be significant as there are currently very limited reports on the 
buccal mucosa as an alternate route of drug administration for ARVs.  The successful delivery 
of the model ARV drugs (TNF, ddI and SQV) via this route would overcome several 
disadvantages associated with their current therapy. The successful identification of polymers 
that have mucoadhesive, controlled release as well as buccal permeation enhancement 
properties would decrease the amount of excipients being incorporated into a dosage form as 
one multifunctional excipient would bring about these desired affects. The advantages of such a 
formulation would be decreased drug-polymer interaction, as the numbers of polymers are 




limited in the formulation. There would also be a decrease in adverse or allergic reactions to the 
patient, and also a decrease in excipient incompatibilities. This type of formulation would also 
decrease manufacturing costs.  
 
The identification of high-energy ball milling as an alternate method to chemical permeation 
enhancers for buccal permeation enhancement will widen the pool of available strategies used 
for permeation enhancement. Methods that preclude the use of chemical enhancers for this 
purpose will decrease the reliance of incorporating chemical enhancers into buccal drug delivery 
formulations. The advantages of using high-energy ball milling as a strategy would include 
decreased chemical interactions or incompatibilities experienced between excipients and drugs 
in drug formulations, as high-energy ball milling is a physical method of promoting drugs 
permeability across the buccal mucosa. Therefore, this study will contribute to formulation 
optimization strategies for buccal delivery systems of ARV drugs.   
 
1.4  NOVELTY OF THIS STUDY 
While other routes for the delivery of antiretroviral drugs have been extensively studied and 
reported, there is a scarcity of data on their buccal delivery potential, which can overcome 
several disadvantages associated with current therapy. For the first time, this study identifies the 
buccal delivery potential of tenofovir (TNF). It also compares the permeability potential of 
tenofovir, and didanosine, two different classes of ARV drugs. Histomorphological evaluations 
are also used to predict their suitability for retention on the mucosae and to predict possible 
permeation mechanisms. The identification of excipients possessing multifunctional properties 
such as mucoadhesivity, controlled release and buccal permeation would be useful for the 
formulation of buccal drug delivery systems. To date, the only polymeric excipient reported so 




far with these three properties is chitosan. This study shows for the first time that PEG, PAA, SA 
and CMC as polymeric excipients, also have buccal permeation enhancing properties and can 
therefore be considered as multifunctional excipients for buccal delivery systems.  The study 
also shows that neither of the two ARV’s alone, or in combination with PEG has any adverse 
affects on the cellular integrity of the buccal mucosa.  
 
Ball milling is widely used as an approach to reduce particle size, as well as for making 
amorphous dispersions that serve to increase the solubility of poorly soluble drugs. We show for 
the first time that ball milling of SQV can be used as a physical method for enhancing its 
permeation across the buccal mucosa. This study therefore displays that ball milling can be 
used as an attractive alternative to chemical enhancers for buccal permeation. For the first time, 
this study also reports on the buccal delivery potential of Saquinavir (SQV). 
 
1.5 OVERVIEW OF THIS DISSERTATION  
Chapter 1 provides an introduction and outlines the background to the study, describing the 
challenges faced with current antiretroviral drug therapy and drug delivery via the buccal route. 
This chapter also explores the rationale for the study and highlights the aim and objectives of 
the study.  
 
Chapter 2 is a literature review, focusing on HIV/AIDS with the current treatments, its limitations 
and strategies employed to overcome these limitations. This chapter also describes the buccal 
route of drug delivery focusing on the structure, advantages and disadvantages of this route, 
barriers of the buccal mucosa to permeation, routes available for permeation across the mucosa 
and methods used to assess mucosal permeation. It explains the need for buccal permeation 
enhancers, as well as the approaches and classes of both physical and chemical enhancers. 




The mechanisms of chemical permeation enhancers are described in this chapter. This chapter 
describes the evaluation of buccal mucosal integrity testing during permeation experiments. 
 
Chapter 3 is an original research article published in an ISI international journal: Journal of 
Pharmaceutical Development and Technology, titled: “Comparative Buccal Permeability 
Enhancement of Didanosine and Tenofovir by Potential Multifunctional Polymeric Excipients 
and their Effects on Porcine Buccal Histology.” This chapter is presented in the required format 
of the journal and is the final revised accepted version. 
 
Chapter 4 is an original research article accepted for publication in an ISI international journal: 
Drug Development and Industrial Pharmacy, titled: “High‐energy ball milling of Saquinavir 
increases permeability across the buccal mucosa.” Manuscript ID: LDDI-2013-0486.R1. This 
chapter is presented in the required format of the journal and is the final revised accepted 
version. 
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CHAPTER 2 – LITERATURE REVIEW 
INTRODUCTION 
This chapter provides an overview of literature relevant to the background of this study. This 
includes the current status of HIV infections, current therapy for HIV and AIDS and the 
limitations to the current therapy. The review describes the approaches to overcome these 
limitations, and the buccal route as an alternate route of drug administration. The advantages 
and disadvantages associated with the buccal route are outlined, together with the methods 
employed to study permeation, and the current strategies to enhance drug permeation, across 
the buccal mucosa.  
   
2.1 HIV AND AIDS 
Human immunodeficiency virus (HIV) is an infectious agent that causes Acquired Immune 
Deficiency Syndrome (AIDS). HIV and AIDS are serious public health diseases and one of the 
main causes of death in sub-Saharan Africa (1, 2).  There are currently 35.3 million people living 
with HIV globally, of whom 71% live in sub-Saharan Africa. Although new HIV infections have 
been reduced by 33% globally since 2001, there were 2.3 million new infections in 2012 (3). 
Despite the decrease in the number of new infections, recent statistics indicate that much still 
remains to be done to stem the pandemic. 
 
HIV is a retrovirus that primarily infects components of the human immune system such as, 
macrophages, dendritic cells and CD4+ T cells, and directly and indirectly destroys the latter. 
Once inside the cell the viral RNA genome is converted into double-stranded DNA by a virally 
encoded reverse transcriptase which is transported with the viral genome in the virus particle. 
The virus and the infected host cell can avoid detection by the immune system if the virus 




becomes latent after integration with the host cell. Alternatively, the replication cycle can be 
initiated if the virus is transcribed, producing new RNA genomes and viral proteins (4,5).  
Two types of HIV have been characterized: HIV-1 and HIV-2. HIV-1 is more virulent and more 
infective, and is the cause of the majority of HIV infections globally (5). Ultimately, HIV causes 
AIDS by depleting CD4+ T cells that weakens the immune system and allows opportunistic 
infections. The primary causes of death from HIV and AIDS are opportunistic infections, which is 
frequently the result of the progressive failure of the immune system (5). In 2012, Tuberculosis 
co-infection was at the forefront of the sicknesses that caused death in those with HIV and 
AIDS.  Tuberculosis is present in a third of all HIV infected people, and caused 25% of HIV 
related deaths (6). HIV can also invade the central nervous system; causing severe neurological 
damage and loss that often leads to HIV associated dementia. Without treatment, HIV infection 
is nearly uniformly fatal (5).  
 
2.1.1 Current therapy for HIV and AIDS 
There is currently no cure or effective HIV vaccine, although ARV drug therapy has significantly 
improved the treatment of HIV and AIDS (1,2). Presently, ARV drugs are classified under the 
following four categories including, protease inhibitors (PI), nucleoside reverse transcriptase 
inhibitors (NRTI), nucleotide reverse transcriptase inhibitors (NtRTI) and non-nucleoside reverse 
transcriptase inhibitors (NNRTI). Treatment of HIV and AIDS consists of Highly Active 
Antiretroviral Therapy (HAART), which is a combination of at least three medications belonging 
to at least two types of antiretroviral drugs (5, 7) and slows the progression of the HIV infection. 
As of 2012, more than 9.7 million people were taking ARVs in low and middle income countries 
(3). Treatment of HIV and AIDS also includes the preventive and active treatment of 
opportunistic infections. 
 




2.1.2 Limitations to current therpay 
Although oral antiretroviral drug therapy has significantly improved the treatment of HIV infection 
and AIDS, several disadvantages are associated with their use. Many ARV drugs have low 
bioavailabilities, due to extensive hepatic first pass effects and gastrointestinal degradation. The 
half-lives for several ARVs are short, thus requiring frequent administration of doses which can 
decrease patient compliance. With frequent dosing, patients are exposed to the risk of severe 
dose-dependent side-effects. Some ARV drugs also experience formulation problems due to 
their physicochemical properties such as poor solubility (2,5).  
 
2.1.3 Approaches to overcome limitations 
Strategies being explored to overcome these limitations include assessing various dosing 
regimens, chemical modification of current drugs (8,9), as well as the development of novel drug 
delivery systems (NDDS) and alternate routes of drug administration for current and new ARV 
drugs (5). ARVs that are susceptible to the above mentioned limitations (see 2.1.2) will benefit 
from these proposed strategies, leading to effective ARV treatment and increased patient 
compliance (2,5). NDDS being explored for ARV drugs include polymeric micelles (10), enteric 
coated and extended release tablets (11), nanoparticles (12,13), liposomes and niosomes 
(14,15). The alternate routes for ARV drug administration being explored are transdermal (16), 
vaginal (17), nasal (18), rectal (19) as well as the buccal (20) routes. The focus of this study is 









2.2 BUCCAL ROUTE OF DRUG DELIVERY 
Most drugs are conventionally introduced into the systemic circulation via the oral route (21). 
However certain drugs exhibit low bioavailability as many of these drugs are subjected to pre-
systemic drug elimination within the gastrointestinal tract and the hepatic system. Drug 
candidates with this property for the treatment of either local or systemic diseases are emerging 
and therefore novel / alternative routes of drug administration are becoming more necessary 
(21,22). 
 
There has been much interest in the use of the mucosal lining of the body cavities as alternative 
routes of drug administration.  As indicated above, there are a number of potential sites for the 
alternative route of drug delivery.  The mucosa lining of the oral cavity comprises of three 
different categories for drug delivery, i.e. sublingual, buccal and local (e.g. gingival) (23). The 
oral mucosal sites differ significantly from each other in terms of structure, the ability to retain a 
delivery system as well as permeability.  The sublingual route is by far the most widely studied 
routes, while the sublingual area is not suited for sustained/controlled drug release as it 
generally provides rapid absorption and high bioavailabilities. The buccal mucosa, which is 
found lining the inside of the cheek, has been explored as an alternative route for drug delivery 
(21-24). Although the buccal mucosa is less permeable than the sublingual mucosa, it is not 
able to give a rapid onset of absorption although it is more suitable for a sustained/controlled 
release formulation (21). 
 
2.2.1 Structure of the buccal mucosa 
The buccal mucosa refers to the mucosa that lines the inside of the cheeks, and is made up of 
approximately 40-50 cell layers, giving it a thickness of between 500 and 800 µm (25). The 
primary role of the buccal mucosa is to protect the underlying tissue from foreign agents. The 




buccal mucosa is a lining mucosa and therefore is nonkeratinized, as compared to the 
keratinized masticatory mucosa lining the oral cavity. Anatomically, the buccal mucosa consists 
of a basement membrane that supports the outermost layer of stratified squamous epithelium.  
 
The basement membrane provides the required adherence between the connective tissue and 
the epithelium (22, 25). The epithelial cells at the basement membrane are actively mitotic, and 
these serve to replenish damaged/dead cells as they advance through the intermediate layers 
to the superficial layer. This ability, coupled with the fast turnover time of 3-8 days, lends to the 
‘rebound’ characteristic of the buccal mucosa. . The epithelial cells increase in size and become 
progressively flatter as they travel from the basal cell layers to the superficial layers (25). The 
basal cells have characteristically larger intercellular spaces between them, compared to cells 
closer to the surface, which are more closely packed. The buccal epithelium is composed of 
many loose intercellular links, such as desmosomes, hemidesmosomes and gap junctions, 
which is similar to nasal and intestinal mucosa.  
 
Beneath the basement membrane lies the lamina propria, followed by the submucosa as the 
innermost layer. The lamina propria serves as a support for the basement membrane and the 
epithelial cells that lie on it (26, 27). This region is comprised mainly of connective tissue, such 
as collagen and smooth muscle. The lamina propria is richly supplied with capillaries and small 
vessels that drain directly into the internal jugular. This capillary network also serves to provide 
nutrition for all layers of the mucosa. The stratified squamous epithelium of the buccal mucosa 
is relatively thicker than the rest of oral mucosa, which therefore makes the buccal mucosa 
more resistant to permanent damage during the application of a dosage form (25,28). (Figure 
2.1) 
 





Figure 2.1: Cross section of the buccal mucosa (29) 
 
 
2.2.2 Advantages of the buccal route 
Drug administration via the buccal route has the following advantages:  
 The bioavailability of drugs administered via this route is increased as degradation in the 
gastrointestinal tract and hepatic portal system is avoided. As compared to orally 
administered drugs, drugs administered via this route are protected from degradation due 
to the digestive enzymes and pH of the gastrointestinal tract (28,30). 
 The buccal mucosa also has an expanse of smooth muscle and relatively immobile 
mucosa that makes it a more desirable region for retentive systems used for oral trans-




mucosal drug delivery, making it more suited morphologically for sustained drug delivery 
applications (28). 
  Drugs can be administered in unconscious or incapacitated patients, demonstrating 
convenience of administration as compared to oral medications (30). 
 There is a relatively rapid onset of action compared to the oral route, and the formulation 
can be removed if therapy is required to be discontinued (25).  
 Although less permeable than the sublingual area, the buccal mucosa is well vascularized, 
and drugs can be rapidly absorbed into the venous system underneath the oral mucosa 
(21).  
 Oral mucosal drug delivery is less variable between patients, resulting in lower inter-
subject variability as compared to transdermal patches (30). 
 There is rapid cellular recovery of the localized site on the smooth surface of the buccal 
mucosa (21).  
 
2.2.3 Disadvantages of the buccal route 
Although the buccal mucosa presents an attractive site for alternate route of drug delivery, there 
are however some limitations to this selection. 
 There is low permeation across the buccal mucosal membrane due to its barrier 
properties. It also has a relatively smaller absorptive surface area in comparison to the 
small intestine (21,25). 
 Drugs that are unstable at buccal pH cannot be administered by this route (23).  
 For systemic delivery, the relative impermeability of oral cavity mucosa, with regard to 
drug absorption, especially for large hydrophilic drugs, is a major concern (27).  




However, the advantages of this route render these disadvantages less significant, which have 
led to substantial research in controlled-release buccal drug delivery systems internationally 
(25). 
 
2.2.4 Barriers to drug permeation across the buccal mucosa 
Comparatively, the major limitation of the buccal route is its low mucosal permeability, especially 
to drugs with larger molecular weights (31), which has been attributed to many factors. The 
mucosal lining all the regions of the oral cavity has a lower permeability than that of the 
intestinal mucosa, which  is due to factors such as anatomical differences in the compositions of 
these tissues, as well as the considerable difference in the surface area available for 
permeation (23,32). When compared to the permeability between the various regions within the 
oral cavity, although the buccal is not the most permeable, it is best suited for a sustained drug 
delivery system (25). The permeability order of the mucosa in the oral cavity indicates the 
palatal mucosa to be less permeable than the buccal mucosa, which in turn is less permeable 
than the sublingual mucosa. These differences in permeability have been largely attributed to 
the degree of keratinization, as well as to the thickness of the mucosa in the different regions 
(28).  
The barrier properties of the buccal mucosa are due to the upper one-third to one-quarter layer 
of the buccal epithelium. As basal cells migrate towards the surface of the epithelium, they 
differentiate and become more flattened, with the subsequent accumulation of lipids and 
proteins.  This further culminates in a portion of the lipid becoming concentrated into small 
organelles called membrane-coating granules (MCGs) (22, 33), which are found in almost all 
stratified squamous epithelium. The MCGs fuse with the intercellular spaces close to the 
surface of the mucosa and release the lipid lamellae. These released lamellae subsequently 




fuse from end to end to form broad lipid sheets in the extracellular matrix, creating the main 
barrier to buccal permeation (23).  
 
When crossing the cellular membranes, this transcellular route involves crossing the polar and 
lipid domain, whereas the paracellular route implicates diffusion through the extracellular lipid 
domain. The lipid matrix of the extracellular spaces therefore play a role in the barrier function of 
the buccal mucosa, especially if the compounds are hydrophilic and have high molecular 
weights (23-28).  Macromolecules and polar compounds traverse the buccal mucosa, utilizing 
the paracellular route of transport. Intercellular tight junctions are one of the major barriers to 
this route of transport (21, 25).  
 
The mucosa also consists of an enzymatic barrier that is present at the surface as well as within 
the mucosa. Although this barrier is less effective than that of the GIT, drugs administered via 
the buccal route need to overcome this barrier in order to reach the systemic circulation. A drug 
will only encounter some of the enzymes of the enzymatic barrier. This is dependent on the 
physicochemical properties of the drug, which dictates its route of transport across the mucosa 
(28, 30). The surface epithelial cells of the buccal mucosa are surrounded by mucus, which, 
although it serves as an excellent delivery vehicle by acting as a lubricant, can form a strongly 
cohesive gel structure that binds to the epithelial surface as a gelatinous layer, posing as a 
barrier to the permeation of drugs (34). While the superficial layers of the oral epithelium are the 
primary barrier to the permeation of drugs; the basement membrane may also present some 
resistance to permeation, limiting the passage of materials across the junction between 
epithelium and connective tissue (28, 29, 35).  
 
 




2.2.5 Factors affecting drug absorption 
Various factors of the drug molecule influence the permeation of the molecule across the buccal 
mucosa. These factors include the molecular weight and size of the drug, the lipid solubility, pKa 
of the drug, degree of ionization and pH of the drug solution and the presence or absence of 
permeation enhancers, all affect the absorption and the permeation of drugs through the oral 
mucosa. These factors are additional to the biochemical and anatomical characteristics of the 
buccal mucosa that are responsible for the barrier function and permeability, (28,30,36).  These 
factors need to be considered when designing a drug formulation for buccal delivery, so as to 
ensure that the combination of the chosen drug and excipients in the formulation allow for 
optimum permeation across the mucosal membrane.  
 
2.2.6 Routes of permeation across the buccal mucosa 
Transporting the substances across the epithelial membranes can occur either by simple 
passive diffusion, active transport or carrier mediated diffusion in addition to other specialized 
mechanisms (21). Simple passive diffusion is the major mechanism involved in transporting 
drugs across the buccal mucosa, with the two major routes being the intercellular (paracellular) 
and the intracellular (transcellular) pathways. The mechanisms, pathways and efficiency of drug 
permeation through the mucosa can be influenced by the physicochemical properties of the 
drug (27,28). Depending on these properties, and as the buccal epithelium is stratified, a 
permeant can use both these routes simultaneously, with one route being usually preferred over 
the other, that being the one that provides the least amount of hindrance to passage (29,37). 
The cell membrane acts as the major barrier to permeation of hydrophilic compounds, as it is 
lipophilic in nature, and the intercellular spaces are the major barrier to the permeation of 
lipophilic compounds, as it is hydrophilic in nature (35). 
 




2.3 METHODS USED TO EVALUATE MUCOSAL PERMEATION 
Identifying permeability properties of a drug and permeation enhancer are critical prior to 
formulation development, with the ability of a drug to permeate the barrier being assessed by in 
vitro, ex vivo, or in vivo methods (21). The low availability of human buccal tissue for 
experimental use has led to the application of various animal models that closely resemble 
human tissue. The main concern of choosing a particular animal model is the resemblance of its 
oral mucosa to that of the human, both in enzymatic activity and ultra-structure. Porcine (pig) 
buccal mucosa has been considered to be a representative model for human buccal mucosa. 
The porcine mucosa resembles that of human more closely than any other animal model in 
terms of composition and structure, and being non-keratinized, its membrane morphology, lipid 
content and composition and permeability barrier functions (21,23,25,38). 
 
Rapid and efficient evaluation of drug permeation across the buccal mucosa has been facilitated 
by the development of cultured normal human cells. Stratified cultured TR146 cell layers have 
been recommended as a valuable new in vitro model for permeability studies, as they are 
equivalent to normal human buccal epithelium. These cells resemble stratified human tissue 
and have originated from a buccal carcinoma. This cell line has been shown to have similar 
permeability properties, morphology and ultra stucture compared to the buccal mucosa. Studies 
on bidirectional permeability have displayed close correlation to the data obtained using human, 
monkey and porcine buccal mucosa (30,34). 
 
The permeability of various drugs across the oral mucosa has been determined using various 
commercially available diffusion devices such as the vertical and horizontal Franz cells, 
continuous flow perfusion chambers, Ussing chambers, Sweetana-Grass  diffusion chambers 
and a choice of various side-by-side flow through cells (25,39). Table 2.1 shows a summary of 




recent studies that performed in vitro diffusion experiments across the buccal mucosa of animal 
models. The most common diffusion device being used for in vitro buccal permeation studies is 
the Franz diffusion cell, and the most common animal model utilized is the porcine (Table 2.1). 
Table 2.1 Recent in vitro diffusion studies across the buccal mucosa using animal 
models. 
DIFFUSION DEVICE DRUG/PERMEANT ANIMAL 
MODEL 
REFERENCE Year of 
Publication 
Franz diffusion cell Carmabazepine, triamcinolone 
acetonide 
Porcine (40) 2011 
Horizontal permeation cells Buspirone, bupivacaine, antipyrine, 
caffeine 
Porcine (41) 2011 
Franz diffusion cell Omeprazole Porcine (42) 2010 
Franz diffusion cell Ondansetron HCL Porcine (43) 2011 
Franz diffusion cell Glibenclamide Sheep (44) 2011 
Franz diffusion cell Naltrexone HCL Porcine (45) 2011 
Ussing chambers Metoprolol Porcine (46) 2013 
Franz diffusion cell Phenylephrine Porcine (47) 2011 
Franz diffusion cell Opioid peptide (DPDPE) Porcine (48) 2011 
Franz diffusion cell 5-Fluorouracil Guinea Pig (49) 2009 
Franz diffusion cell Didanosine Porcine (20) 2012 
Franz diffusion cell Ropinirole Porcine (50) 2012 
Franz diffusion cell Salmon Calcitonin Porcine (51) 2011 
Franz diffusion cell Didanosine Porcine (52) 2013 
 
2.4  BUCCAL PERMEATION ENHANCERS 
Diffusion is solely responsible for the non-enhanced delivery of a drug across the buccal 
mucosa, which could have inadequate permeability of certain drugs, depending on their 
physicochemical properties (21-24). The lower permeability of the buccal mucosa, coupled with 
the limited surface area available for permeation, leads to inadequate absorption of drug into the 
systemic circulation. Therefore, various enhancement strategies are required to deliver 
therapeutically relevant amounts of the drug into the systemic circulation. One of the limiting 
factors for many drugs in the development of a buccal delivery device is membrane permeation 
(25-28,30,35). Permeation enhancers are substances that promote the absorption of a drug 




through the buccal mucosa. They could promote the permeation of drugs through the epithelium 
of the buccal mucosa by decreasing their barrier properties by different mechanisms. Generally, 
enhancement in buccal drug delivery is sub-divided into physical or chemical methods (53), and 
finding a safe and effective permeation enhancer is a priority.  
 
2.4.1 Physical methods 
A number of physical methods of permeation enhancement have been explored, with 
supersaturation, thermal enhancement, iontophoresis, electroporation and sonophoresis being 
explored further. 
 
2.4.1.1 Supersaturation  
This method does not alter the physicochemical properties of the drug, nor does it modify 
the structure of the mucosal membrane. In a supersaturated dosage form, the 
concentration of the drug in a vehicle is greater than the solubility i.e. the vehicle contains 
more dissolved material than could be dissolved in normal conditions (54). In these 
formulations, the drug has a high tendency to leave the vehicle, which increases the 
concentration gradient and flux rates across the mucosal membrane. However, this 
method of enhancement is dependent on the stability of the formulations, which is 
currently limited (55). 
 
2.4.1.2 Thermal enhancement  
The key parameter for this process is the activation energy of diffusion which, in turn, is 
dependent on temperature (56). This method is useful for drugs with high lipophilicity, as 
they have lower activation energies of diffusion. It has been suggested that an accurate 
increase in temperature may be used in drug delivery devices as a means of increasing 




permeation across the mucosal membrane (57,58). This method is however limited by the 
range of temperature and requires complex delivery devices that are able to regulate 
temperature (53).   
 
2.4.1.3 Iontophoresis  
This is an electrical assisted method used to overcome the barrier properties of the buccal 
mucosa, and has been extensively considered to enhance the buccal permeability of 
drugs form different therapeutic classes with a variety of physicochemical properties. This 
method utilizes an electric field to assist the passage of molecules through the biological 
tissue, with small amounts of physiologically acceptable electric current forcing the 
passage of charged drugs into the tissue. Drug permeation increases when the current 
density grows (24). This method has been extensively studied for transdermal delivery, 
with several devices marketed for this purpose. However, it has been reported that in 
order to improve transbuccal transport, iontophoresis should be combined with chemical 
penetration enhancers (59). This method is restricted by the complexity of the devices 
required for its application, and the limit to the current densities that can be applied, with 
the method being considered to be minimally invasive (53). 
 
2.4.1.4 Electroporation  
This is another electrical method used to promote the permeation of molecules across the 
mucosal membrane, and has been extensively studied for transdermal application (60). 
This method applies high electric field pulses for a very short period of time, which induce 
the movement of particles and perturbation of the lipid bilayers inside the membrane. As a 
result, the structural rearrangements lead to the formation of new aqueous pathways (60). 
Drug flux can be controlled by adjustment of the voltage, and time of exposure and total 




number of pulses delivered (61). This method is limited by the complexity of the delivery 
device required, as well as careful monitoring of the applied voltage. This method is also 
considered to be minimally invasive, with the application of high currents leading to 
possible membrane damages (62). 
 
2.4.1.5 Sonophoresis  
Ultrasound is classified based on three frequencies: high, medium and low, with  low 
frequency (sonophoresis) being found to induce drug transport enhancement rather than 
high frequencies. While ultrasound application has been used for transdermal drug 
delivery, this technique may also be used for drug enhancement across the mucosal 
membrane (63). The application of ultrasound on biological tissues implies several 
concurrent phenomena including: convection, cavitational, thermal and mechanical 
effects. The latter three thermal and mechanical effects have the greatest influence on 
increasing the permeability enhancement, which is mainly brought about by disrupting the 
lipid bilayer and the formation of water channels. The extent of the enhancement induced 
by sonophoresis depends on frequency and intensity as well as duty cycle and application 
time. This approach also requires the use of a complex delivery device and is also 












2.4.2 Chemical methods 
The use of chemical permeation enhancers is the most widely used approach to enhance 
buccal absorption, and can be classified into many categories depending on their chemistry and 
their mechanism of action (65). The detailed chemical classification is tabulated in Table 2.2. An 
ideal chemical enhancer to be considered for formulation into a buccal drug delivery dosage 
form should have the following characteristics (28, 30, 65): 
 Non-toxic, non-irritating and non-allergenic. 
 Pharmacologically and chemically inert. 
 The absorption enhancement action should be immediate and unidirectional.  
 The effect of the permeation enhancer should be reversible i.e. after removal of the 
dosage from the mucosal surface; the tissue should immediately fully recover its normal 
barrier properties. 
 The enhancer should be compatible with a wide range of drugs and pharmaceutical 
excipients.  
Factors that can affect the selection of the permeation enhancer and the efficacy of the 
enhancer are (28): 
 Physicochemical properties of the drug to be incorporated into the formulation. 
 Nature of the vehicle. 
 Other excipients added in the formulation. 
A combination of permeation enhancers generally shows a greater effect than the use of 
individual permeation enhancers (28). Depending on the site of administration, the efficacy of 
permeation enhancers may vary due to differences in functional and structural properties, such 
as membrane thickness, lipid composition, enzymatic activity, cellular morphology and potential 




protein interactions. Penetration enhancement via the buccal membrane is also drug specific 
(66).  
 
Table 2.2 Classes of permeation enhancers and their mechanisms of action (adapted 
from Hassan et al., 2010). 
Class of chemical 
enhancer 
example Mechanism of action 
Bile salts Sodium-taurocholate, 




Reduction of mucus viscosity 
Peptidase inhibition 
Denaturation of proteins 
High concentration – disrupt cell membrane 
lipids  




laurate, sorbitan laurate, 
glycerol monolaurate, 
polysorbate 20 and 80 
Phospholipids acyl chain disruption 
Membrane fluidization 
Producing reverse micellization in the 
membrane and creating aqueous channels 
Extraction of membrane proteins and lipids 
Solubilization of peptides  
Fatty acids Oleic acid, caprylic acid, 
lauric acid, 
palmitoylcarnitine  
Phospholipid acyl chain perturbation 
Disruption of intercellular lipid packing 
thereby increasing membrane fluidity 
Polymers Chitosan salts, trimethyl 
chitosan 
Ionic interactions with negatively charged 
groups of glycocalyx 
Inclusion 
complexes 
α-,β- and γ-cyclodextrins, 
methylated β-cyclodextrins 




acid (EDTA), citric acid, 
salicylates, polyacrylates 
Complexation of Ca2+ to maintain 
intercellular spaces, thereby permitting 
paracellular transport.     
Opening of tight junctions 
 
2.4.2.1 Bile salts 
Bile salts are the natural or synthetic salts of cholanic acid, play an important role in the 
absorption of lipids and lipid-soluble vitamins, with all those excreted from the liver being 
conjugated with either glycine or taurine. Their physiological role is to enable fat digestion 
and absorption through the intestinal walls by emulsifying lipids in food that passes 




through the intestine (28).These compounds are believed to act due to a number of 
reasons, such as by extracting lipid components of the mucosa, extracting proteins, 
membrane fluidization, reverse micellization in the membrane and creating aqueous pores 
(65). Studies have shown that bile salts at lower concentrations are affecting only the 
paracellular route of transport. However, at higher concentrations, both the paracellular as 
well as the transcellular routes are affected (30). At lower concentrations, bile salts 
possibly solubilize the intercellular lipids and thereby enhance the paracellular route. Apart 
from the extraction of mucosal lipids, bile salts have also been shown to cause uncoiling 
and extension of protein helices, which also encourages transport via the paracellular 
route (34). At higher concentrations, bile salts disrupt the cell membrane lipids, thus 
enhancing the transcellular route. Bile salts have been extensively used to enhance the 
absorption of drugs through the oral mucosa, and it is generally considered that changes 
caused to the oral mucosa by this method are reversible (65). 
 
2.4.2.2 Surfactants  
Anionic surfactants are used in many cleaning and hygiene products, and being a 
detergent, these molecules have amphiphilic properties (34), including being 
predominantly water soluble and forming associations (micelles) in aqueous solution. The 
cationic and nonionic surfactants have also proven to be effective permeation enhancers. 
The actions of surfactants are very similar to those of the bile salts described above (28), 
namely the swelling of tissues, protein denaturation and extraction of lipids (30). Studies 
have also shown that like bile salts, surfactants are able to increase both the transcellular 
as well as paracellular routes of transport at higher concentrations. Their action is mainly 
brought about by the solubilization of membrane components, which leads to changes in 
cellular membrane permeability (65). 




2.4.2.3 Fatty acids  
Fatty acids are the most abundant lipids in biological cell membranes, and although there 
are numerous reports of fatty acids being used as transdermal permeation enhancers, 
very few reports are available on their buccal permeation enhancement potential. Medium 
chain length fatty acids have been shown to be more effective than longer chain, or 
shorter chain length fatty acids. The administrations of cis-unsaturated fatty acids have 
been reported to increase membrane permeability by disruption of intercellular lipid 
packing and increasing fluidity (34). Saturated fatty acids have been shown to be less 
disruptive than unsaturated fatty acids with the same chain length. It has  also been 
demonstrated that the extent of enhancement using fatty acids are dependent on a few 
factors, such as the chain length, degree of branching, presence and position of double 
bonds, fatty acid concentration and contact time (30). Studies have also shown that fatty 
acids are less irritating than bile salts and surfactants. Furthermore, long chain fatty acids 
and their analogs are suited to the enhancement of lipophilic drugs, whereas medium 
chain length fatty acids and their derivatives can be used for both hydrophilic and lipophilic 
drugs (34, 67). 
 
2.4.2.4 Chitosan and derivatives    
In recent years, chitosan and its derivatives have received much attention in the literature 
for its absorption-enhancing effects, having been proven that these compounds are 
potential absorption enhancers for mucosal delivery systems. The literature shows that 
chitosan has a significant effect on enhancing permeation of various therapeutic agents 
and peptides across the buccal mucosa (68). Various mechanisms have been proposed 
for the mode of permeation enhancement of chitosan and its derivatives. Studies suggest 
that the enhancement effect may be related to the direct fluidization effect on intercellular 




lamellae, and the bioadhesive nature of chitosan, which ensures a greater residence time 
(28,65). It has also been reported that chitosan can open the tight junctions between 
epithelial cells, thereby enhancing permeation via the paracellular route. Chitosan exhibits 
several favorable properties, such as its permeation enhancement effect, biocompatibility, 
biodegradability, bioadhesion, antifungal and antimicrobial properties, which makes it an 
ideal candidate for incorporation as a multifunctional excipient into a buccal drug delivery 
formulation (28, 34). 
 
2.4.2.5 Cyclodextrins 
Cyclodextrins have been used as complexing agents in an effort to increase membrane 
permeability, being enzymatically modified starches, forming rings of 6-8 units. The outer 
surface of the ring is polar, whereas the internal surface is non-polar. The formation of 
inclusion complexes is therefore possible whereby the the center of the cyclodextrin can 
be used to carry water-insoluble molecules in an aqueous environment (30). Drug 
absorption and bioavailability across the buccal mucosa is increased by first solubilizing 
poorly water-soluble drugs via complexation with cyclodextrins. The opening of tight 
junctions and the alteration of mucosal permeability is the most probable mechanism of 
action of cyclodexrins as absorption enhancers (65). 
 
2.4.2.6 Azone  
Azone is used extensively as a transdermal permeation enhancer, and it has been 
proposed that it was able to form ion pairs with anionic drugs to promote their permeation. 
Azone has also found use in buccal drug delivery to enhance molecules across the 
membrane (34), and was shown to interact with the lipid domains and alter the molecular 
moment on the surface of the bilayers. The enhancing effect of Azone on buccal mucosa 




has been attributed to it being able to increase the reservoir capacity of the buccal 
epithelium and to also increase of the fluidity of lipids in the mucosal membrane (35).  
 
2.4.2.7 Vehicles  
To improve transport, drugs can be dissolved or dispersed in a solvent with the 
mechanism being categorized as follows (28):  
 Increasing the degree of saturation in the vehicle resulting in a change in the 
thermodynamic activity. 
  Facilitate partitioning of drug from the vehicle in the mucosa.  
 
2.4.2.8 Enzyme inhibitors  
Although the oral cavity is not as enzymatically active as the gastrointestinal tract, the 
environment of the oral cavity and oral epithelium is relatively enzymatic. This causes 
reduced bioavailability of some drugs that are susceptible to this enzymatic degradation 
before they are absorbed (28). In order to overcome this short-coming, research has been 
directed into the use of enzyme inhibitors, with the literature showing that co-
administration of a drug with enzyme inhibitors improves the buccal absorption of drugs. 
Bile salts and protease inhibitors and have also been shown to stabilize peptides against 
buccal mucosal enzymes (34). 
 
2.4.3 Mechanisms of action of buccal permeation enhancers 
Buccal mucosal absorption is increased by the use of permeation/penetration enhancers. 
Although various classes of enhancers are available, many may exhibit similar mechanism of 
action, which have been classified as changing mucus rheology, increasing the fluidity of lipid 




bilayer membrane, acting on the components at tight junctions, by overcoming the enzymatic 
barrier and increase in the thermodynamic activity of drugs.  
 
2.4.3.1 Changing mucus rheology (28,65) 
Buccal drug permeation is largely hindered by the thickness of mucus viscoelastic layer, 
while saliva covering the mucus layers also hinders the permeation. Some permeation 
enhancers diminish the viscosity of the mucus and saliva, overcomes this barrier.  
 
2.4.3.2 Increasing the fluidity of lipid bilayer membrane (28,30,65) 
The intracellular route is the most preferred route of buccal permeation. Permeation 
enhancers using this mechanism perturb the intracellular lipid packing by interaction with 
lipid or protein components.  
 
2.4.3.3 Acting on the components at tight junctions (28,65) 
Larger molecules pass through the buccal mucosa via the intracellular route, with tight 
junctions and similar interconnections hindering the movement of mainly macromolecules 
across the buccal mucosa. In this mechanism, permeation enhancer’s act on 
desmosomes, a foremost component at the tight junctions, which enhances drug 
absorption via the intracellular route.  
 
2.4.3.4 By overcoming the enzymatic barrier (28,30) 
These permeation enhancers achieve their effect by altering the action of various 
peptidases and proteases inside buccal mucosa, in this way they are able to overcome 
the enzymatic barrier. Additionally the enzymatic activity is indirectly altered by the 
modification in membrane fluidity.  




. 2.4.3.5 Increase in the thermodynamic activity of drugs  
Some permeation enhancers alter the partition coefficient of the drug and thus increase 
the solubility. The escalation in the thermodynamic activity results in improved drug 
permeation across the buccal mucosal membrane. 
 
 
Figure 2.2: Schematic representation of penetration routes in buccal drug delivery, 








2.5 EVALUATION OF MUCOSAL INTEGRITY 
With the availability of human buccal mucosal tissue being very limited to perform in-vitro 
permeation experiments, scientists have explored the use mucosal cell culture as well as animal 
models for this purpose. The porcine buccal mucosa has been considered to be a 
representative model, as it resembles human tissue more closely than any other animal model 
(21, 25). In order to perform the perfusion experiments required for such studies, authors have 
used both fresh and frozen membranes (25). Studies have shown that there are negligible 
differences between experiments that compared frozen membrane to fresh (40). However, the 
uses of integrity markers are vital as positive controls in such studies (25). These tests should 
be performed before and after the experiment to ensure the integrity of the membrane during 
the experiment. Transepithelial electrical resistance (TEER) is a method commonly used to 
assess membrane integrity. TEER is able to detect minute tears in the membrane, which is 
represented by alterations in the electrical resistance between the donor and receptor cells. 
Performing the test before the experiment ensures that there was no damage to the membrane 
during the harvesting, excising or the storage processes of the membrane prior to the 
experiment. The second test after completion of the experiment confirms that the drug 














The literature indicates the advantages of the buccal route of drug administration, with ARV 
drugs that are susceptible to degradation in the gastrointestinal tract and/or hepatic first pass 
metabolism show potential for delivery via this route. With limited studies available on the 
delivery of ARVs through the buccal mucosa, further drugs from this class need to be identified 
for administration. With the major limitation of this route being the low membrane permeability, 
the literature shows various approaches adopted to overcome them. Permeation enhancers 
have proven to be critical in delivering adequate amounts of the drug via the buccal mucosa, 
therefore necessitating the identification of more buccal permeation enhancers.  These 
enhancers will serve to increase the selection available to formulation scientists for 
incorporation into buccal drug delivery systems. The chemical approach to permeation 
enhancement is at the forefront of buccal permeation enhancement studies; however, there has 
recently been an increased investigation of alternate approaches to enhancing permeability 
across the buccal mucosa. The development of new approaches is vital to increase the pool of 
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This study identified and compared the buccal permeability properties of antiretroviral drugs; 
didanosine (ddI) and tenofovir (TNF), and the permeability effects of polymeric excipients i.e. 
carboxymethyl cellulose (CMC), sodium alginate (SA), polyacrylic acid (PAA) and polyethylene 
glycol (PEG) as potential multifunctional excipients for buccal drug delivery.  Permeation studies 
across porcine buccal mucosa were performed and the drug was quantified using UV 
spectrophotometry. The mean flux for both ddI (113-181 g/cm2hr) and TNF (40-102 g/cm2hr) 
increased linearly with increasing donor concentration. All polymeric excipients improved 
permeability of TNF while only PEG was effective for ddI. Permeability enhancement ratios at 
20 mg/mL for ddI and TNF were 1.63 and 1.74 respectively, using PEG (0.5% w/v) and CMC 
(0.5% w/v), respectively. The maximum enhancement ratio of 2.13 for TNF was achieved with 
4% w/v PEG. Light and transmission electron microscopy revealed no significant loss in cellular 
integrity for mucosa treated with either TNF or ddI alone or when coupled with PEG as a 
polymeric enhancer. Histomorphological observations correlated with flux values obtained for 
TNF and ddI alone, as well as with PEG’s effects on drug mass flux. TNF and ddI have 
demonstrated buccal delivery potential. Selective polymeric excipients provide an effective 
means to increase their penetration and may serve as potential formulation multifunctional 
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Drug delivery via the buccal route is receiving increasing interest  as an alternative to oral and 
other conventional routes of administration for the following reasons: It is able to bypass 
enzymatic degradation and hepatic first pass metabolism, improving  bioavailability (1, 2)  and is 
not influenced by  variations in  gastric emptying rate or the presence of food. As compared to 
the skin for transdermal delivery, the permeability of the buccal mucosa is higher and cell 
recovery is also more rapid, and it has easier access than nasal, rectal and vaginal mucosae. 
The buccal mucosa is also more resistant to irritation, and has greater patient acceptability than 
other non-oral routes. Buccal delivery systems are also advantageous for pediatrics and 
patients with a swallowing problem (3, 4). Although oral antiretroviral drug (ARV) therapy has 
significantly improved the treatment of HIV (Human Immunodeficiency Virus) infection and AIDS 
(Acquired Immune Deficiency Syndrome), one of the most serious public health diseases (5, 6); 
several disadvantages are associated with their use. Many ARV drugs have a low 
bioavailability, as well as short half-lives, and therefore require frequent administration that 
decreases patient compliance and leads to severe dose dependent side-effects. Furthermore, 
some may lead to formulation difficulties  due to poor solubility (7). These ARV drugs may 
therefore benefit from buccal drug delivery. While ARV drugs have been more widely studied for 
the transdermal route to overcome the above disadvantages (8-11), data on their buccal 
permeability potential appear to be limited (12, 13) . Tenofovir (TNF), a nucleotide analog, is 
widely used in the treatment of HIV/AIDS.  Due to its hydrophilicity and poor intestinal 
permeability it is currently administered orally as the ester prodrug; tenofovir disoproxil 
fumarate.  Buccal delivery of TNF in its base form will allow for increased bioavailability and will 
obviate the need for synthesizing and using the current prodrug.  Furthermore, while TNF has 
been investigated for transdermal (14)  and vaginal routes (15), it’s  buccal delivery potential still 




remains to be identified. Didanosine (2’3’-dideoxyinosine; ddI) is a dideoxy analogue of the 
purine nucleoside inosine (16) and is also used in the treatment of HIV AIDS. However, it is 
characterized by a short half-life of 1.3-1.6 hours, extensive first pass metabolism (23-40% 
bioavailability), gastrointestinal pH degradation and severe dose dependent side-effects (14, 
17). ddI is therefore also an ideal ARV candidate for controlled release buccal delivery.  
The advantages of the buccal route has led to the design and evaluation of various buccal 
delivery systems  such as tablets, films, wafers, patches, gels and pastes (18). The benefit of 
these buccal delivery systems can be enhanced by ensuring that the drug is released in a 
controlled manner. Various polymers both alone or in combination, are used in buccal delivery 
systems to modify drug release profiles via several mechanisms, such as erosion, swelling and 
hydration (19).  
 
One of the main disadvantages of the buccal route is the low mucosal permeability, 
necessitating the use of various classes of permeation enhancers. These enhancers alter 
mucosal permeability by various mechanisms, such as changing the mucus rheology, disturbing 
the intracellular lipid packing in the bilayer  and the loosening of tight junctions (1). Substances 
such as surfactants, fatty acids, cyclodextrins, chelators and positively charged polymers have 
been identified in the literature as buccal permeation enhancers (7). The search and 
identification of new drugs and permeation enhancers via in vitro permeation studies with drug 
and potential enhancer solutions is currently a major focus of research in the literature to widen 
the available pool of drug and excipients and consequently inform the selection of excipients for 
formulation into future buccal delivery systems.  
 
To facilitate prolonged retention on the mucosae allowing for sustained delivery and permeation; 
buccal delivery systems also need to display mucoadhesivity i.e. they need to adhere to the 




mucus layer covering the buccal mucosae. In order to meet the challenges of buccal delivery, 
the key properties therefore needed for a buccal drug delivery system are: 1) drug permeation 
enhancement; 2) mucoadhesivity and 3) controlled drug release profiles. The identification of 
formulation excipients to provide these properties is therefore critical.  Various polymers such as 
cellulose derivatives, and those based on polymethacrylic acid, polysaccharides and alginic acid 
have  successfully shown  mucoadhesivity and sustained drug release properties (20). 
 
The identification of excipients with potential multifunctional properties such as mucoadhesivity, 
drug permeation enhancement and controlled drug release profiles, will significantly contribute 
to the optimization of the design of buccal delivery systems. The multifunctional properties 
required for buccal delivery systems has led investigators to study, separately, different classes 
of excipients as permeation enhancers and polymers that have either or both mucoadhesivity 
and controlled release properties. Clearly, a need exists for the use of multifunctional 
pharmaceutical excipients in the design of buccal delivery systems i.e. excipients that could 
simultaneously provide mucoadhesivity, sustained drug release and permeation enhancement. 
The use of multifunctional excipients for buccal drug delivery will decrease the number and 
quantity of excipients needed in product formulation. Advantages include decreased 
manufacturing costs, adverse or allergic reactions and excipient incompatibilities. To date, to the 
best of our knowledge, the only excipient thus far reported in separate studies to have 
mucoadhesive, sustained release and permeation enhancing properties; has been chitosan (20, 
21). Hence the need exists for the identification of excipients that could have multifunctional 
properties such as mucoadhesivity, sustained drug release and drug permeation enhancement 
capabilities. While various excipients such as poly(acrylic acid) (21), sodium alginate (21), 
poly(ethylene glycol) (19, 20) and carboxymethylcellulose (21, 22)are  recognized  as having 




both sustained drug release and mucoadhesivity properties, their buccal permeability 
enhancement potential still remains to be investigated.  
 
The aim of this study was therefore to firstly identify and compare the buccal permeability 
potential of two ARV drugs i.e. didanosine (ddI) and tenofovir (TNF). The second aim was to 
determine the effects of poly (acrylic acid), sodium alginate, poly (ethylene glycol) and 
carboxymethylcellulose on the permeation of these drugs as well as their histomorphological 
effects on the buccal mucosae as potential multifunctional formulation excipients for buccal 
delivery. 
 
PEG was particularly chosen in this study to further investigate its potential as an enhancer as it 
proved to be the only polymer that was able to increase the permeability of both TNF and ddI. 
Also PEG has been reported to be strongly mucoadhesive due to hydrogen bonding between 
either oxygen atoms in PEG and sugars on glycosylated mucins, and/or interpenetrating 
polymer network (IPN) effects between PEG chains and the mucus mesh (42). This interaction 
with the mucus to enable PEG’s mucoadhesivity could also be beneficial in decreasing the 
barrier properties displayed by the mucus to the movement of molecules across the mucosa.  
 
2. MATERIALS 
The buccal mucosal tissue was obtained from Baynesfield Abattoir (Pietermaritzburg, South 
Africa), from pigs weighing approximately 60-80 kg. Phosphate buffered saline (PBS), pH 7.4, 
was prepared using sodium chloride, potassium dihydro-orthophosphate and disodium 
hydrogen orthophosphate (Associated Chemical Enterprises, South Africa). Excipients 
(Carboxymethyl Cellulose (CMC) MW = 90000 Da, Sodium Alginate (SA), Poly acrylic acid 
(PAA) MW = 1800 Da, and Polyethylene Glycol (PEG) MW = 4000 Da) were purchased from 




Sigma-Aldrich (USA).  Tenofovir (TNF) MW = 287.21 g/mol was obtained from Gilead Sciences, 




3.1 Ethical Clearance 
Ethical clearance was obtained from the UKZN Ethics committee in 2010 (010/10/Animal) and 
renewed in 2011 (24/11/Animal). 
 
3.2 Tissue preparation 
Porcine buccal tissue as obtained from the pigs immediately after slaughter.  The tissues were 
excised, using surgical scissors, to remove all underlying tissue, to a thickness of between 500-
700 µm, leaving the basal lamina intact. The tissues were transported in cold, normal saline 
(NS), snap frozen in liquid nitrogen, stored in a biofreezer (-80˚C) and used within three months 
(23). Cold PBS (pH 7.4) was used to defrost the buccal mucosal tissue at room temperature 
before it was used in permeation studies.   
 
3.3 Permeation Measurement across Porcine Buccal Mucosa  
In vitro permeation studies were conducted at 37±1˚C using modified vertical Franz type 
diffusion cells (PermeGear, Inc., Bethlehem, USA) with a diffusional area of 0.786 cm2. A 
circular section of the buccal mucosa was mounted onto the diffusional area between the donor 
and receptor cells and was equilibrated with PBS (pH 7.4) at 37°C for 30 minutes.  The donor 
compartment solution (1 mL) contained either drug (TNF/ddI) with PBS alone (20 mg/mL) or 
drug (TNF/ddI) (20 mg/mL) in the presence of the various excipients (PAA, SA, CMC and PEG) 
at a concentration of 0.5% w/v in respective experiments. The concentration dependent effect of 




PEG, specifically, on the enhancement of drug (TNF/ddI)  permeation, was performed with the 
donor compartment solution (1 mL) containing drug (TNF/ddI) (20 mg/mL) in the presence of 
various concentrations of PEG (0.25, 0.5, 1.0, 2.0, 4.0 and 6.0% w/v). The receptor 
compartments were filled with PBS and stirred with a teflon-coated magnetic bar. Samples were 
removed from the receptor compartments at predetermined time intervals and replaced with the 
same volume of ddI/TNF–free (fresh) PBS. Each experiment represents minimum of three 
replicates. The drugs were quantified by a validated UV spectrophotometry method at a λmax of 
262 nm and 250 nm, for TNF and ddI, respectively (UV Spectrophotometer 1650, Shimadzu, 
Japan) which are similar to other buccal permeability studies. 
 
3.4 Permeability data analysis  
The cumulative amount of drug (TNF/ddI) permeated per unit surface area was plotted 
against time. The steady state flux (Jss) was determined from the linear part of the 
permeability curve by linear regression analysis (Microsoft Excel 2007, USA). The 
permeability coefficient (P) was calculated as follows (24): 
 
   [1] 
   
dQ/dt is the cumulative amount permeated per unit time, A is the diffusion area and Cd is 
the drug concentration in the donor compartment.  The enhancement ratio (ER) was 
calculated using the following equation (24): 
 
             [2] 
 




3.5 Light Microscopy and Transmission Electron Microscopy 
Histological evaluations were performed on freshly harvested, excised buccal mucosa. 
Untreated buccal mucosa was transferred directly after excision from normal saline into 10% 
buffered formalin without any equilibration in PBS and served as the control. Treated samples 
comprised of buccal mucosa that were exposed to PBS only, or 20 mg/mL TNF dissolved in 
PBS alone or 20 mg/mL ddI dissolved in PBS alone, or 20 mg/mL TNF dissolved in PBS with 
4% w/v PEG, or 20 mg/mL ddI dissolved in PBS with 0.5% w/v PEG. Permeation experiments 
were carried out with these solutions in the donor compartment; and with the freshly excised 
buccal mucosa placed between donor and receptor compartments as described in 3.3 above, 
without  drug quantification (12, 25). At the end of the experiment the buccal mucosa was 
removed from the Franz diffusion cells, cut into cross sections and fixed in 10% buffered 
formalin. Both the control and treated buccal mucosa were fixed in formalin for 7 days at room 
temperature. Buccal mucosa was dehydrated using an ethanol gradient ranging from 50% up to 
96% and embedded in paraffin wax. The mucosae sections were collected on slides, dried and 
stained with hematoxylin and eosin (H&E). Sections were examined using a light microscope 
(Nikon 80i, Japan) and bright field images were digitally captured using NIS Elements D 
software and a camera (Nikon U2, Japan). The samples for transmission electron microscopy 
(TEM) were obtained after the above mentioned permeation experiments. The samples were 
then cut into pieces not exceeding 0.5 mm3, and fixed for 24 hours (4°C) using Karnovsky’s 
fixative (26) buffered to pH 7.2. For TEM, each sample was processed and embedded in epoxy 
resin using standard protocols. Ultrathin sections (90 nm) were cut and contrasted with uranyl 
acetate and lead citrate and viewed with a transmission electron microscope (JEOL 1010, 
Japan). All experiments were performed using a minimum of three replicates. 
 




3.6 Statistical Analysis 
The results, expressed as mean ± standard deviation (SD), were analyzed using  one-way 
analysis of variance (ANOVA) followed by the Mann Whitney test using GraphPad Prism® 
(Graph Pad Software Inc., Version 5., USA).   
 
4. RESULTS AND DISCUSSION 
4.1 Buccal permeability profiles of TNF and ddI 
The permeability potential of TNF and ddI, were first investigated in the absence of an 
enhancer. Increasing the donor concentrations (1 to 20 mg/mL) led to an increase in the 
cumulative amount permeated across the buccal mucosa for both drugs. The flux of TNF and 
ddI at the varying donor concentrations are shown in Figure 1. Both TNF and ddI were able to 
permeate the buccal mucosa at increasing concentrations. The results obtained displayed 
concentration dependant permeability for both ARV drugs. For TNF, as the donor concentration 
increased from 1 mg/mL to 20 mg/mL, the steady state flux increased from 40.18 ± 8.85 to 
102.1 ± 19.80 µg/cm2hr (Table 1). While the increase in flux at lower concentrations from 1 to 
7.5 mg/mL were not significant (p > 0.05), statistically significant differences were seen at the 
higher concentrations of 10 and 20 mg/mL (P < 0.05). One-way ANOVA for the various 
concentrations of TNF were also significantly different (P < 0.05). For ddI, as the donor 
concentration increased, flux values increased from 113.4 ± 6.85 to 181.62 ± 23.62 µg/cm2 hr. 
The increases in flux values from 1 mg/mL to 20 mg/mL were statistically different (P < 0.05) 
and one-way ANOVA for the various concentrations of ddI studied were also significantly 
different (P < 0.05).  An apparent linear relationship between the donor concentrations and flux 
values for both TNF (R2 = 0.94) and ddI (R2 = 0.82) was observed (Figure 2). These findings 
suggest passive diffusion of both the drugs across the mucosa (4, 7, 27). 
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Figure 1: Effect of drug concentration on mean flux and mean permeability coefficients for TNF 
























40.18 ± 8.85 
43.41 ± 18.35 
44.51 ± 21.38 
49.95 ± 9.83 
*57.43 ± 7.88 
*102.10 ± 19.80 
ddI 
113.4 ± 6.85 
*142.4 ± 17.84 
*144.62 ± 13.36 
*158.19 ± 36.53 
*160.02 ± 35.69 
*181.62 ± 23.62 
TNF 
4.01 ± 0.88 
1.73 ± 0.73 
0.89 ± 0.42 
0.66 ± 0.13 
0.57 ± 0.07 
0.51 ± 0.09 
ddI 
11.34 ± 0.71 
5.69 ± 0.71 
2.89 ± 0.26 
2.10 ± 0.48 
1.60 ± 0.14 
0.90 ± 0.11 
* Indicates significant difference i.e P < 0.05 (All values compared to 1mg/mL)  
 
Figure 2: Effect of donor concentration on the steady state flux. 




Since the buccal epithelium is stratified, a permeant can use either the transcellular or 
paracellular route or both the routes simultaneously. However one route is usually preferred 
over the other, favoring the one that provides the least amount of hindrance to passage. The 
physicochemical properties of a drug can also influence the mechanisms of transport across the 
buccal mucosa. The permeation of many hydrophilic drugs across the buccal mucosa is thought 
to be via the paracellular route using passive diffusion (7, 22,  28-30). These hydrophilic drugs 
are therefore able to dissolve more readily in the aqueous fluid of the intercellular spaces; 
however, the lipid matrix of the extracellular spaces plays a role in the barrier function of the 
buccal mucosa especially if the compounds have high molecular weights (28, 29). Tight 
junctions act as major barriers to paracellular transport of macromolecules and polar 
compounds (2, 7, 31).  Hence both of these hydrophilic drugs may have used the paracellular 
route, however a higher ionization at pH 7.4 of ddI (pKa=9.12) as compared to that of TNF 
(pKa= 7.9) suggests that ddI is the more capable permeant via this route (32, 33).  This is 
illustrated by higher mean flux and permeability coefficient observed for ddI (Table 1). Although 
both drugs displayed increased permeability with increasing concentrations, ddI displayed 
greater flux values than TNF at similar concentrations. This could be also attributed to ddI’s 
lower molecular weight as compared to TNF, thus allowing greater permeability. The donor 
concentration range of the drug solutions of this study was in keeping with previous such 
permeability studies (13)  and the flux values obtained in this study for TNF and ddI are similar 
to, or greater than flux values that have been reported for other drugs identified as having 
potential for buccal delivery also via in vitro permeation studies (13, 34). TNF and ddI may be 
considered as having the potential for improving HIV/AIDS drug therapy when administered via 
the buccal mucosa instead of the oral route. 
 




4.2 Effects of polymeric excipients on permeability enhancement 
Polymeric excipients of varying ionic charges were employed as potential permeation 
enhancers for TNF (as an anionic drug) and ddI (as a cationic drug). Permeation/penetration 
enhancers promote the absorption of a drug across the buccal mucosa by decreasing its barrier 
properties, delivering therapeutically relevant amounts of the drug into the systemic circulation. 
Hydrophilic drugs, such as TNF and ddI, could both show increased permeability if they are 
coupled with enhancers that are able to either decrease the interaction of the drug with the lipid 
matrix of the extracellular spaces and/or temporarily alter tight junction or both. To identify their 
multifunctional capabilities, polymeric excipients with previously reported controlled release and 
mucoadhesive properties (23, 25, 35); were used as potential enhancers for the buccal delivery 
of TNF and ddI, respectively. The respective enhancers were added to the donor chamber at 
0.5% w/v which is in keeping with previous studies (13, 36). The results of this study showed 
that the permeability of TNF was increased in the presence of all the excipients (Figure 3). CMC 
displayed the greatest increase in mean flux value, which increased from 102.10 ± 19.80 
µg/cm2hr to 178.12 ± 12.87 µg/cm2 with an enhancement ratio of 1.74 (Table 2). All of the 
excipients displayed permeation enhancement for TNF, however the anionic excipients 
displayed the greatest enhancement. These findings may be attributed to the anionic polymers 
having strong hydrogen bonding with mucin, altering the mucus rheology and enhancing 
permeability (23, 35). While the increases in flux values were statistically significant (p < 0.05) 
for CMC, PEG and PAA, CMC displayed the greatest enhancement ratio. The permeability of 
ddI was increased in the presence of the nonionic excipient PEG, whereas the addition of all the 
anionic excipients (PAA, SA and CMC) caused a decrease in the flux values obtained (Table 2). 
Changes in the mean flux and permeability coefficient may have resulted from the anionic 
excipients’ complexation with the positively charged drug, ddI, forming an aggregate which 
hindered movement across the buccal mucosa. In this study the effect of permeant modifiers 




appears to be dependent on the ionic charge of the enhancer and drug. The permeation 
enhancement ratios obtained using PAA, SA, CMC and PEG for TNF and ddI in this study are 
similar to ratios of other permeants reported as promising enhancers in the literature (36, 37). 
This study has confirmed that in addition to their previously reported controlled-release and 
mucoadhesive properties in the literature, these polymeric excipients can also enhance buccal 
drug permeability and may therefore be regarded as promising multifunctional excipients in the 









































Figure 3:  Effect of various multifunctional excipients on the mean flux of TNF and ddI across 
buccal mucosa. 
 





















102.10 ± 19.80 
*158.80 ± 10.19 
174.46 ± 66.56 
*178.12 ± 12.87 
*132.82 ± 9.95 
ddI 
181.62 ± 23.62 
*127.07 ± 7.30 
179.61 ± 52.24 
*136.45 ± 12.29 
*295.94 ± 15.24 
TNF 
0.51 ± 0.09 
0.79 ± 0.05 
0.87 ± 0.33 
0.89 ± 0.06 
0.66 ± 0.04 
ddI 
0.90 ± 0.11 
0.63 ± 0.03 
0.90 ± 0.26 
0.68 ± 0.06 













* Indicates significant difference i.e P < 0.05 (All values compared to Control (20 mg/mL TNF/ddI)  
 
4.3 Effect of Polyethylene Glycol concentrations on permeability 
PEG was the only excipient that displayed enhanced permeation for both TNF (ER = 1.3) and 
ddI (ER = 1.63) (Table 2), and was selected to evaluate its effects on the permeability of TNF 
and ddI. The effect of PEG, within a concentration range of 0.25 – 6% w/v on the permeability of 
TNF and ddI was investigated. This concentration range is in keeping with previous reports (13, 
36). The mean flux values obtained for TNF was increased, with the addition of PEG from 0.25 
to 4% w/v (Figure 4). PEG, at 4% w/v, displayed the greatest  enhancement ratio (ER = 2.13) 
and the greatest increase in mean flux value viz.from 102.1 ± 19.80 to 217.49 ± 18.88 µg/cm2hr  
(Table 3). An  increase in PEG concentration above 4% w/v, resulted in a decrease in the mean 
flux values, from 217.49 ± 18.88 to 195.54 ± 17.57 µg/cm2hr (ER = 1.91) (Figure 4). The mean 
flux values obtained for ddI was increased with the addition of PEG from 0.25 to 4% w/v. PEG at 
0.5% w/v displayed the greatest enhancement ratio (ER = 1.63) and the greatest increase in 
mean flux value which increased from 181.62 ± 23.62 to 295.94 ± 15.24 µg/cm2hr. A further 
increase in PEG concentration from 0.5 to 6% w/v resulted in a decrease in mean flux values 




obtained, which decreased from 295.94 ± 15.24 to 155.85 ± 11.25 µg/cm2hr (ER = 0.86) (Table 
3). Similar trends have been reported, where an enhancer (Aloe vera gel or propylene glycol) at 
varying concentrations, was coupled with a permeant. These studies reported an initial increase 
in flux values with an increase in enhancer concentration and with a subsequent decrease in 
flux values as the enhancer concentration was further increased (13, 38).  
 
PEG’s  mucoadhesion property has been attributed to its ability to increase hydrogen bonding 
and facilitating adherence to the mucosae (39). One of the mechanisms of buccal permeation 
enhancement results from the alteration of the mucus rheology (23, 35), which could account for 
PEG increasing the permeation of both TNF and ddI. PEG, at a lower concentration 0.5% w/v, 
achieved the greatest enhancement of the lower molecular weight drug ddI, whereas for the 
higher molecular weight drug TNF, maximal enhancement was achieved at a higher 
concentration of PEG (viz. 4% w/v). Possible differences in drug interactions could have 
resulted in the decreased movement across the buccal mucosae at higher concentrations than 
the aforementioned. The permeation enhancement ratios achieved with the addition of PEG in 
this study is similar to other studies that identified promising enhancers (32, 36-38). In addition 
to its mucoadhesive and controlled release properties, PEG also showed permeation 
enhancement properties. PEG displayed the greatest enhancement potential for TNF and ddI at 
a concentration of 4% and at 0.5% w/v, respectively, and could be considered when formulating 
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Figure 4: Effect of PEG concentration on permeation enhancement ratio, mean mass flux and 




























102.10 ± 19.80 
130.43 ± 12.83 
*132.82 ± 9.95 
158.34 ± 13.63 
*176.50 ± 29.70 
*217.49 ± 18.88 
*195.54 ± 17.57 
ddI 
181.62 ± 23.62 
*199.66 ± 4.54 
*295.94 ± 15.24 
235.81 ± 58.36 
*228.79 ± 41.41 
183.01 ± 10.93 
*155.85 ± 11.25 
TNF 
0.51 ± 0.09 
0.65 ± 0.07 
0.66 ± 0.05 
0.79 ± 0.06 
0.88 ± 0.14 
1.08 ± 0.09 
0.97 ± 0.08 
ddI 
0.90 ± 0.11 
0.99 ± 0.02 
1.48 ± 0.07 
1.17 ± 0.29 
1.14 ± 0.20 
0.91 ± 0.05 

















* Indicates significant difference i.e P < 0.05 (All values compared to Control (20 mg/mL TNF/ddI)  
4.4 Histomorphological evaluations 
The effect of the ARV drugs (TNF and ddI) and the optimal enhancer identified in this study i.e. 
PEG on the buccal mucosa was investigated histomorphologically. These studies were 
performed to assess whether or not the expected changes following permeation, are of a nature 
that is deleterious to cell i.e. whether cellular integrity has been compromised. Also, these 
studies may indicate to a possible transport mechanism for these drugs and enhancer. The 
criteria for the use of permeation enhancers are that they should be non-irritant and nontoxic, 
and allow the mucosa to rebound to its former integrity (7). In this study we are able to comment 
on the level of perturbation, however, whether or not the cells would regain their former 
morphology requires further investigation. Two routes have been proposed for movement of 
molecules across the buccal mucosae i.e. paracellular and transcellular (2). Although limited, 
from this study, inferences can be made on the mode of transport employed by the molecule 
(drug) and the permeation enhancer, PEG. The mucosa of the buccal lining has been 




extensively described (25). Briefly, histologically, the mucosal layer is made of basal cells which 
are actively mitotic and represent the germinal layer which gives rise to newer cells; a mid-
region where cells acquire a more polygonal shape and surface cells which appear more 
flattened. This description matched our control sample which was not subjected to any 
experimental procedure (Figure 5a).  
 
When compared to the controls, mucosae exposed to the drugs only, ddI and TNF, at 20 mg/mL 
(Figure 5b and 5c respectively) also retained relatively normal histomorphology i.e. no major 
loss of cellular integrity. TNF treatment, however, resulted in mild distortion of cellular outlines 
and desquamation, and an increase in the size of intercellular spaces was observed in electron 
micrographs. The ddI treatment resulted in a vacuolated appearance inside some of the cells 
which was observed both in LM and TEM images (Figure 5e and 6g respectively) unlike those 
of TNF (5b and 6b respectively).  These vacuoles may indicate a possible transcellular mode of 
transport (40). These histomorphological observations appear to correlate with the permeation 
data (Table 1,3 and Figure 2,4 ) where ddI displayed greater permeation in comparison to TNF, 
both in the presence and absence of PEG (Table 1 and  Table 2). Combining both the 
permeability data and histomorphological evaluations, it can be speculated that TNF permeation 
may follow the paracellular route while ddI may use both the paracellular and transcellular 
routes. Substances may use many several modes of transport for movement, including carrier-
mediated transport across the epithelium lining; therefore further investigations are needed to 
confirm how ddI, TNF and PEG move across the mucosal barrier, including an investigation on 
possible endosomal transport mechanisms. Furthermore, the vacuolated appearance may not 
be considered deleterious and these findings are similar to Dhiman et al., (2009) who also found 
a vacuolated appearance in the buccal mucosa after permeation experiments using sodium 
tauroglycocholate as an enhancer. 



































Figure  5: Photomicrographs of the control and 
the treated buccal mucosal selections for light 
microscopy (LM) stained with H&E ; (× 40) a 
control/untreated, b treated with 20mg/ml TNF, c 
treated with 20mg/ml ddI, d treated with 20mg/ml 
TNF + 4% (w/v) PEG, e treated with 20mg/ml ddI 
+ 0.5% (w/v) PEG. 
 




In addition electron micrographs, compared to control (Figure 6a), also revealed an increase in 
the size of intercellular spaces when exposed to both drugs (Figure 6b and 6c respectively). The 
distinct expanded intercellular spaces observed for both drug treatments can be corroborated by 
the assertion that hydrophilic drugs could dissolve in the aqueous intercellular space, and 
therefore favor the paracellular route of absorption (25, 33).  
Using LM we were unable to establish a loss in cellular integrity when PEG was coupled with 
both ddI and TNF at 0.5% and 4% w/v respectively (Figure 5d and 5e). However, using TEM, 
larger intercellular spaces were observed with the addition of PEG to both drugs (Figure 6d and 
6e respectively). These larger intercellular spaces may be responsible for the increased 
permeability observed with the addition of PEG (36). We also observed an increase in nuclear 
invaginations and changes in the nuclear envelopes; (TNF + 4% w/v PEG electron micrographs) 
(Figure 6f). The mechanisms and functional significance of this is not really known but studies 
suggest the involvement of the cytoskeleton (41). We speculate that, in this study, a 
combination of factors such as mechanical stress, ionic changes and increased cellular activity 
may have led to these effects; in response to the permeation experiments. These changes 














































Figure  6: Electromicrographs of the control and the 
treated buccal mucosal selections for transmission 
electron microscopy (TEM ) : a control/untreated  (× 
10000), b TNF 20mg/ml (× 5000), c ddi 20mg/ml (× 
5000), d  TNF + 4% PEG(× 5000), e ddI + 0.5% PEG(× 
5000)  , f TNF + 0.5% PEG showing nuclear 
invagination (× 15000), g ddI 20mg/ml showing 
intracellular vacuoles (× 15000). 
 





This study investigated the buccal delivery potential of two ARV drugs, ddI and TNF. It further 
demonstrated the effects of polymeric excipients on the buccal permeation of ddI and TNF. Both 
TNF and ddI were able to permeate the buccal mucosa in a concentration dependent manner at 
similar concentrations, with ddI having the greater permeability. The permeation of these drugs 
used alone can be attributed to passive diffusion via the paracellular route with transcellular 
route, being an additional possibility for ddI. The addition of all polymeric excipients, i.e. PAA, 
SA, CMC and PEG, used in this study increased the permeability of TNF, however only PEG 
was able to increase the permeability of ddI. The effect of these polymeric excipients and that of 
the drug appeared to be dependent on their ionic charge. Histological investigations revealed no 
significant loss in cellular integrity for mucosa treated with either TNF or ddI, alone, or when 
coupled with PEG as an enhancer. The differences in histomorphological changes in response 
to TNF and ddI alone, could support the greater permeation observed with ddI.  
Selective polymeric excipients provide an effective means to increase the penetration of ddI and 
TNF. Their previously reported mucoadhesive and controlled release properties coupled with 
their permeation enhancing effects shown in this study highlight their potential use as 
multifunctional excipients for the design of buccal drug delivery systems.  
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Saquinavir (SQV), a candidate for buccal drug delivery, is limited by poor solubility. This study 
identified the effects of high energy ball milling on the buccal permeability of SQV and compared 
it to the effects of chemical enhancers i.e. Ethylenediaminetetraacetic acid (EDTA), Sodium 
lauryl sulphate (SLS), Polyethylene glycol (PEG) and Beta Cyclodextrin (ß-cyclodextrin). SQV 
was ball milled using a high energy planetary mill (1, 3, 15 and 30 hr) and permeation studies 
across porcine buccal mucosa were performed using franz diffusion cells. Drug was quantified 
by UV spectrophotometry. Both unmilled and milled SQV samples were able to permeate the 
buccal mucosa. Milled samples of 15 hr displayed the greatest flux of 10.40 ± 1.24 µg/cm2hr 
and an enhancement ratio of 2.61. All enhancers were able to increase the buccal permeability 
of unmilled SQV, with SLS achieving the greatest flux (6.99 ± 0.7 µg/cm2 ) and an enhancement 
ratio of 1.75. However, all the milled SQV samples displayed greater permeability than SLS, the 
best chemical enhancer for unmilled SQV. Enhanced permeability by ball milling was attributed 
to reduction in particle size, formation of solid dispersions and an increase in solubility of milled 
samples. Microscopical evaluation revealed no significant loss in mucosal cellular integrity 
treated with either unmilled or milled SQV. Histological studies suggest that SQV uses both the 
paracellular and transcellular route of transport across the mucosa, with drug treatment having 
no permanent affects. High energy ball milling was superior to the chemical enhancers studied 





Keywords: buccal permeability, saquinavir, ball milling, permeation enhancer, histology 






HIV (Human Immunodeficiency Virus) infection and AIDS (Acquired Immune Deficiency 
Syndrome) is one of the most serious public health diseases and the main cause of death in 
sub-Saharan Africa1,2.  Although oral antiretroviral (ARV) drug therapy has significantly 
improved the treatment of HIV/AIDS, several disadvantages are associated with their use. 
HIV/AIDS drugs administered via the conventional oral route are exposed to the risk of pre-
systemic degradation in the gastrointestinal tract, therefore decreasing bioavailability3,4. Short 
half-lives require frequent administration of doses, which decrease patient compliance, and 
severe dose dependent side-effects may also occur, and some may display formulation 
problems due to poor solubility5. Alternate routes of drug administration over the oral route have 
therefore been widely studied to help overcome these limitations.  
The buccal route of drug administration has received significant attention in the literature, 
enabling them to bypass enzymatic degradation and hepatic first pass metabolism, thereby 
improving the systemic bioavailability of various drugs6-8. In addition, absorption following buccal 
route administration is not influenced by potential variations in the gastric emptying rate or the 
presence of food9. Another route of administration is the skin, but despite the ease of 
application, permeability of the buccal mucosa is higher and cell recovery is also more rapid10. 
The buccal mucosa also has a larger area for drug application, is more easy accessibility 
compared to the nasal, rectal and vaginal mucosa11, and is more resistant to tissue damage or 
irritation12. In addition, buccal delivery systems can be easily applied and removed, has a high 
patient acceptability compared to other non-oral routes of drug administration13,  will  be 
advantageous for pediatrics and patients with swallowing problems. The epithelium found lining 
the buccal mucosa of the pig is stratified squamous epithelium, and resembles that of the 




human more closely than any other animal in terms of structure and composition. With its main 
function being to withstand abrasion due to mastication and to remain lubricated to protect 
against mechanical abrasion, this epithelial lining remains unkeratinized and therefore an 
attractive site for drug delivery8, 14. ARV drugs may benefit from buccal drug delivery, and the 
literature indicates that Tenofovir, Didanosine and Zalcitabine have been studied for their buccal 
permeation properties. While ARV drugs have been more widely studied for their transdermal 
route of administration15-18, research on their buccal permeability properties appear to be 
limited19,20, necessitating further studies on optimizing their delivery via this route.  
Saquinavir (SQV) an ARV drug, belongs to the protease inhibitor class of ARV’s, and is one of 
the new and effective classes of first-line therapies for HIV/AIDS, and inhibits both HIV-1 and 
HIV-2 proteases. SQV has low aqueous solubility, and has a very low systemic bioavailability 
when administered orally, this being a function of incomplete absorption and high first pass 
metabolism in the gut and liver3, 4, 21-23. While SQV may therefore be an ideal candidate for 
buccal drug delivery, this route of administration for may be limited by its poor solubility. 
Strategies that enhance the solubility of SQV will therefore be required for delivery via the 
buccal route. 
 
Common approaches used to enhance low aqueous solubility of drugs include methods that 
reduce particle size (including microsizing and nanosizing), increase their solubilization in co-
solvents, improve their complexation with cyclodextrins, or for the delivery of lipophilic drugs, 
use lipid-based vehicles as well as solid dispersion technology21,24-26. Although some of these 
techniques have been effective at enhancing oral bioavailability for specific compounds, 
success is usually marginal and highly dependent on the physicochemical properties of the 
drug. Poorly soluble drugs, including some poorly soluble ARVs, have been studied in the 




literature using a number of these strategies to enhance their aqueous solubility. Chiappetta et 
al. conducted a study that encapsulated Efavirenz in polymeric micelles to improve its aqueous 
solubility with positive results27. However, it has been highlighted in the literature that concerns 
over storage stability, nanotoxicity and a limited number of polymers available for clinical use for 
this type of formulation may be limiting factors to this approach28. Further research should 
therefore be done on other strategies to enhance the solubility of poorly water-soluble drugs.  
With the addition of polymeric micelles, Chen et al. describes in detail the various strategies 
used for the nanonization of poorly soluble drugs such as the formation of nanoemulsions, as 
well as drug nanocrystals. This is the most widely used strategy to increase the oral 
bioavailability of hydrophobic drugs, with nanoprecipitation, high-pressure homogenization and 
media milling being the most preferred preparations28.  These strategies have shown significant 
promise, with many water-insoluble drugs approved for clinical use or under clinical trials28,29. 
The ‘top down’ technologies, such as media milling to produce drug nanocrystals, are preferred 
to the ‘bottom up’ (precipitation) methods. Media milling can process milligram quantities in a 
rapid screening mode in an early discovery stage, and can also facilitate the possibilities of 
large-scale production for market, therefore offering a promising alternative to enhance solubility 
of poorly soluble drugs29.  
 
The formation of amorphous solids or solid dispersions also presents a promising approach to 
overcome limited solubility of poorly soluble drug24, 30-32. Although milling is an approach widely 
used to reduce particle size, it is not commonly used for making amorphous dispersions, despite 
being shown to be suitable for this purpose33. A recent study by Caron et al. showed that ball 
milling is a viable process for producing amorphous dispersions of sulfonamide33, while Al-
Obaidi et al. indicated the advantages of using ball milling to prepare solid dispersions of 




griseofulvin34. High energy ball milling has the advantage of generating an amorphous system 
while simultaneously promoting the formation of reduced particle size21.  
 
In a previous study by our group, high energy ball milling was used to prepare solid dispersions 
of SQV with optimal surface area and porosity in order to overcome its limited solubility. Milled 
samples were extensively characterized using nuclear magnetic resonance spectroscopy 
(NMR), attenuate total reflectance-infrared spectroscopy (ATR-IR), differential scanning 
calorimetry/thermogravimetric analysis (DSC/TGA), X-ray power diffraction (XRD) and BET 
surface area and porosity. It was also characterized using field emissions scanning electron 
microscopy (FESEM) and solubility studies to determine the effects of ball milling on the solid-
state characteristics and aqueous solubility of SQV21. The results showed that the milled SQV 
samples displayed a decrease in particle size, the formation of solid dispersions and an 
increased solubility in simulated saliva. High energy ball milling displayed a 9-fold increase in 
the solubility of SQV in simulated saliva at pH 6.821, which may promote its permeation across 
the buccal mucosa. However, the subsequent effect of these ball milled samples on buccal 
permeation parameters such as steady state flux and permeability coefficient have not been 
reported, and neither has the permeation of SQV through the buccal route been studied. 
Therefore, based on the suitability for ARV delivery, there is a need to investigate whether the 
ball milling can improve the buccal permeation of SQV. 
 
One of the main disadvantages of the buccal route is the low mucosal permeability that impedes 
optimal permeation of drug, necessitating use of permeation enhancers for the drug to permeate 
across the mucosa8. These permeation enhancers alter mucosal permeability by various 
mechanisms, such as changing the mucus rheology, disturbing the intracellular lipid packing in 
the bilayer membrane and loosening the tight junctions between cell6,8.  There are various 




classes of permeation enhancers, namely surfactants, fatty acids, cyclodextrins, chelators and 
others. Ethylenediaminetetraacetic acid (EDTA) belongs to the chelator class of buccal 
permeation enhancers, this class being known to increase buccal permeability by interfering 
with Ca2+ to maintain the intercellular spaces, thereby permitting paracellular transport. Sodium 
lauryl sulphate (SLS) belongs to the surfactant class of enhancers that act by extracting 
membrane protein or lipids, assisting membrane fluidization, or producing reverse micellization 
in the membrane and creating aqueous channels, thereby increasing the permeability of the 
drug/compound. ß cyclodextrin belongs to the cyclodextrin class of enhancers and acts via the 
inclusion of membrane compounds to increase the membrane permeability. PEG, recently 
identified as a multifunctional excipient in our laboratory, has shown promise as a buccal 
permeation enhancer6,35. The effect of these various classes of enhancers on SQV have not 
been reported, and a study comparing the effects of high energy ball milling as a strategy for 
permeation enhancement, compared to typical examples from the various classes of chemical 
enhancers, has not been undertaken. 
 
The aims of this study were therefore to investigate the buccal permeability potential of SQV, 
and to evaluate the effects of high energy ball milling on the permeability parameters of SQV. 
The effects of various classes of commonly used permeation enhancers on the permeability of 
SQV were also investigated and compared to high energy ball milling as an approach to 
enhancing buccal permeability. In addition, it evaluated the histomorphological effects of both 










2.1 Ethical Clearance 
Ethical clearance was obtained from the University of KwaZulu-Natal Ethics committee in 2010 
(010/10/Animal), and renewed in 2011 (24/11/Animal) and 2012 (08/12/Animal). 
 
2.2 Materials 
The buccal mucosal tissue was obtained from Baynesfield Abattoir (Pietermaritzburg, South 
Africa), from pigs weighing approximately 60-80 kg. Phosphate buffered saline (PBS) with a pH 
7.4 was prepared using sodium chloride, potassium dihydro-orthophosphate and disodium 
hydrogen orthophosphate (Associated Chemical Enterprises, South Africa). 
Ethylenediaminetetraacetic acid (EDTA), Sodium lauryl sulphate (SLS), Polyethylene glycol 
(PEG) and Beta Cyclodextrin (ß-cyclodextrin) was purchased from Sigma-Aldrich. Saquinavir 
mesylate (MW = 767.0 g/mol) was kindly donated by Hoffmann- La Roche Ltd. (Basel, 
Switzerland) and analyzed both before and after milling for 1–30 hr. 
 
2.3 Preparation of nanoporous saquinavir: high-energy ball milling 
The ball milling was performed in a high-energy planetary mill (Retsch PM 400) at room 
temperature under compressed air. Stainless steel milling jars (250 mL) containing an 
appropriate mass of stainless steel balls (15 mm) were used to mill the samples. One gram of 
SQV was milled for 1, 3, 15, and 30 hr in each jar, with a ball/sample weight ratio of 30:1. The 
speed of the solar disk was set to 200 rpm. The milled and unmilled samples were 
characterized in terms of solubility, melting point, density, particle size, BET surface area, pore 
volume and pore size, and is presented in Table 1, as previously reported by our group21. 
 
 




Table 1: Saquinavir mesylate solid state characteristics (21).  
Ball milling time (hr) 0 1 3 15 30 
Solubility (mg/ml) 0.293 ± 0.07 1.349 ± 0.03 2.986 ± 0.02 2.279 ± 0.01 2.979 ± 0.01 
Density (g/ml) 1.149 1.197 1.168 1.210 1.172 
Particle size (nm) 1030 912 355 3400 n/d 
BET surface area (m2/g) 5.069 ±0.17 5.470 ± 0.15 14.43 ± 0.36 1.455 ± 0.092 n/d 
Pore volume (µL/g) 20.0 29.0 41.0 11 n/d 
Pore size (nm) 15.59 23.29 11.29 30.58 n/d 
 
2.4 Tissue preparation 
The porcine buccal tissue was harvested using surgical scissors from the pigs immediately after 
slaughter. The tissues were excised, using surgical scissors, to remove all underlying excess 
tissue to a thickness of between 500-700 µm, leaving the basal lamina intact. The excised 
tissues were transported in cold, normal saline (NS), snap frozen in liquid nitrogen within 30 
minutes after excision, stored in a biofreezer (-80˚C) and used within three months19,35. Cold 
PBS (pH 7.4) was used to defrost the buccal mucosal tissue at room temperature for 45 minutes 
before it was used in permeation studies.  
 
2.5 Permeation Measurement across Porcine Buccal Mucosa  
In vitro permeation studies were conducted at 37±1˚C using modified vertical Franz type 
diffusion cells (PermeGear, Inc., Bethlehem, USA) with a diffusional area of 0.786 cm2. A 
circular section of the buccal mucosa was mounted onto the diffusional area between the donor 
and receptor cells, and was equilibrated with PBS (pH 7.4) at 37°C for 30 minutes.  The donor 




compartment solution contained either SQV unmilled or milled samples dissolved in PBS (20 
µg/ml), or SQV unmilled in the presence of the various enhancers (BCD, EDTA, PEG and SLS) 
at a concentration of 0.5% w/v in respective experiments. The receptor compartments were 
filled with PBS and stirred with a teflon-coated magnetic bar. Samples were removed from the 
receptor compartments at predetermined time intervals and replaced with the same volume of 
SQV–free (fresh) PBS. Each experiment represents a minimum of three replicates. The drug 
was quantified by a validated UV spectrophotometry method at a λmax of 239 nm (UV 
Spectrophotometer 1650, Shimadzu, Japan), which are similar to other buccal permeability 
studies19, 35. 
 
2.6 Permeability data analysis  
The cumulative amount of drug (SQV) permeated per unit surface area was plotted against 
time. The steady state flux (Jss) was determined from the linear part of the permeability curve 
by linear regression analysis (Microsoft Excel 2007, USA). The permeability coefficient (P) was 
calculated as follows19, 35: 
  [1] 
dQ/dt is the cumulative amount permeated per unit time, A is the diffusion area and Cd is the 
drug concentration in the donor compartment. The enhancement ratio (ER) was calculated 
using the following equation19, 35: 
 








2.7 Transepithelial electrical resistance (TEER) studies  
The integrity of the buccal mucosa was assessed by transepithelial electrical resistance (TEER) 
measurements using a Millicell ERSmeter (Millipore, USA) connected to a pair of chopstick 
electrodes (STX01). TEER measurements were taken across the mucosa prior to, and at the 
end of the permeation experiment37. TEER values at time zero were used as 100%. The 
rebound effect of the mucosa post drug treatment was measured by removing the drug solution 
from the donor compartment after a period of six hours and replacing it with fresh PBS for a 
period of two hours with subsequent TEER measurements38. 
 
2.8 Light Microscopy and Transmission Electron Microscopy for Histomorphological 
evaluations 
Histological evaluations were performed on freshly harvested, excised buccal mucosa. 
Untreated buccal mucosa was transferred directly after excision from normal saline into 10% 
buffered formalin without any equilibration in PBS, and served as the control. Treated samples 
consisted of buccal mucosa that were exposed to PBS only, or 20 µg/mL SQV (unmilled) 
dissolved in PBS or 20 µg/mL SQV (1 hr milled) dissolved in PBS or 20 µg/mL SQVM (15 hr 
milled). Permeation experiments were carried out with these solutions in the donor 
compartment, and with the freshly excised buccal mucosa placed between donor and receptor 
compartments as described in 2.5 above, without drug quantification19, 20, 35. At the end of the 
experiment, the buccal mucosa was removed from the Franz diffusion cells, cut into cross 
sections and fixed in 10% buffered formalin. Both the control and treated buccal mucosa were 
fixed in formalin for seven days at room temperature. Buccal mucosa was dehydrated using an 
ethanol gradient ranging from 50% up to 96% and embedded in paraffin wax. The mucosae 
sections were collected on slides, dried and stained with hematoxylin and eosin (H&E). Sections 
were examined using a light microscope (Nikon 80i, Japan), and bright field images were 




digitally captured using NIS Elements D software and a camera (Nikon U2, Japan). The 
samples for transmission electron microscopy (TEM) were obtained after the above mentioned 
permeation experiments. The samples were then cut into pieces not exceeding 0.5 mm3, and 
fixed for 24 hours (4°C) using Karnovsky’s fixative39 buffered to pH 7.2. For TEM, each sample 
was processed and embedded in epoxy resin using standard protocols. Ultrathin sections (90 
nm) were cut and contrasted with uranyl acetate and lead citrate, and were viewed with a 
transmission electron microscope (JEOL 1010, Japan). All experiments were performed using a 
minimum of three replicates. 
 
2.9 Statistical Analysis 
The results, expressed as mean ± standard deviation (SD), were analyzed using  one-way 
analysis of variance (ANOVA) followed by the Mann Whitney test using GraphPad Prism® 
(Graph Pad Software Inc., Version 5., USA).  A p value of less than 0.05 was considered 
statistically significant. 
 
3. RESULTS AND DISCUSSION 
3.1 Buccal permeability of SQV 
The permeability potential of unmilled SQV was first investigated, with the results displaying a 
maximal cumulative amount of 28.78 ± 2.18 µg/cm2 (Figure 1) and a steady state flux value of 
3.99 ± 0.11 µg/cm2hr (Table 2). These buccal permeability parameters were comparable to 
other drugs such as risperidone, ondansetron HCl and 5-aza-2-deoxycytidine which have been 
investigated for buccal drug delivery40-42. A series of milled SQV samples (1, 3, 15 and 30 hours 
milled) were then studied to determine their effects on the permeability parameters. Milling the 
SQV for one hour led to a significant increase (p < 0.05) in the steady state flux, as compared to 




the control, which increased from 3.99 ± 0.11 µg/cm2hr to 10.30 ± 0.85 µg/cm2hr (Table 2), and 
represents an enhancement ratio (ER) of 2.58. This decreased particle size (912 nm), displayed 
by the one hour milled sample compared to the control (1030 nm), is responsible for the 
increase in solubility and resulting increased permeability21. Raising the milling time to three 
hours also led to a significant increase (p < 0.05) in the flux value 7.99 ± 0.34 µg/cm2hr 
compared to the control.  However, this increase was lower (ER= 2) than those obtained using 
the one hour milled sample (Table 2). These findings can be explained by the physicochemical 
properties of the three hour sample, which displayed a lower particle size of 355 nm compared 
the control (Table 1).  




















































Figure 1: Effect of milling time on the cumulative amount of SQV permeated across the buccal 
mucosa. 
 




Table 2: Effect of ball milled SQV samples on buccal permeability properties 




unmilled SQV 3.99 ± 0.11 19.95 ± 0.57 
 
1hour milled *10.30 ± 0.85 51.53 ± 4.25 2.58 
3 hour milled *7.99 ± 0.34 39.95 ± 1.71 2 
15hour milled *10.40 ± 1.24 52.01 ± 6.21 2.61 
30 hour milled *7.18 ± 1.38 35.93 ± 6.92 1.8 
* Indicates significant difference i.e p < 0.05 (all values compared to unmilled SQV) 
Although the reduction in particle size was responsible for the increased solubility, there was an 
increase in surface area to 14.43 ± 0.36 nm compared to the 5.47 ± 0.15 nm of the one hour 
milled sample (Table 1). The increase in surface area combined with the reduced particle size of 
the three hour sample could have increased the interaction between drug molecules, and 
resulted some of these particles possibly forming complexes, thereby slightly hindering the 
permeation of the drug across the mucosa and reducing the flux values. Increasing the milling 
time to 15 hours displayed a highest ER of 2.61 with a cumulative amount of 77.21 ± 4.53 
µg/cm2 (Figure 1) and steady state flux value of 10.40 ± 1.24 µg/cm2hr (Table 2). This resulted 
in an increase in the particle size and a decrease in the surface area when compared to the 
control and the one and three hour samples (Table 1).  
 
Despite this increase in the particle size, the solubility was not reduced when compared to the 
three hour sample, which displayed the highest solubility (Table 1). A previous paper showed 
that this was attributed to the formation of solid dispersions in samples milled for at least 15 
hours21. Furthermore, SQV exhibiting extended pseudo-polymorphism undergoes polymorphic 
changes during ball milling. At 15 and 30 h period of ball milling, new but unstable polymorphic 




structures of SQV are formed21. These polymorphic conversions and generation of amorphous 
mixture due to loss of water of hydration during ball milling results in materials referred as solid 
dispersions43-46. The loss of crystalline water upon extensive grinding results in very hygroscopic 
drug solids45-47 and many researchers have shown previously that amorphous drug requires 
lower activation energy for dissolution than its crystalline form48-50. Therefore, it can be assumed 
that formation of more soluble polymorphic forms and hygroscopic drug solids together have 
contributed to highest ER of 15 h milled samples. The 15 hour milled sample has a higher 
solubility than the one hour milled sample (Table 1), which explains the slightly higher values 
obtained using the former. The 15 hour sample also displayed the largest pore size of all the 
milled samples (Table 1), indicating that milled samples with a larger pore size (i.e. 1 and 15 
hour) have a greater permeability.   
A further increase in milling time from 15 hours to 30 hours produced a sample that also 
displayed enhanced permeability compared to the control, being able to attain a cumulative 
amount of 54 ± 6.10 µg/cm2 and an increase in mean steady state flux from 3.99 ± 0.11 
µg/cm2hr to 7.18 ± 1.38 µg/cm2hr (Table 2) with an ER of 1.8. Although these values are greater 
than that of the control, the values obtained for the 30 hour milled sample were the lowest of the 
milled samples. Branham et al., 2012 reported that the greatest increases in solubility of SQV 
was observed at the lower end of the milling range, and as the milling time increased from 30 
and 60 hours, the solubility of SQV decreased, with drug aggregates forming after 15 hour 
milling. These results support the data observed in this study, with the decrease in solubility and 
aggregate formation beyond 15 hours possibly being responsible for the decrease in 
permeability observed with 30 hour milled SQV sample. In previous studies will ball milled SQV, 
XRD diffractograms indicated a gradual crystalline to amorphous transition with milling time. 
Also, surface micrographs of pellets of SQV before and after milling indicated differences. 




Unmilled SQV consisted of fused plate-like crystalline structures whilst milled SQV showed a 
smooth glassy microstructure21. Therefore these changes in crystallinity and morphology may 
have also resulted in the enhanced permeation of SQV with ball milling. The maximal 
enhancement ratio obtained using the milled samples compares favourably with the 
enhancement ratios reported by previous studies using chemical permeation enhancers, such 
as sodium tauroglychocholate, carboxymethyl cellulose, sodium algenate and methyl-beta-
cyclodextrin, for enhancement across the buccal mucosa35, 51, 52.  
 
Transepithelial electrical resistance (TEER) measurements were taken prior to and after 
permeation experiments using the milled samples to identify the mucosal integrity during 
permeation experiments. TEER measurements were also taken two hours post permeation, with 
the drug solution in the donor compartment being replaced with fresh PBS. TEER 
measurements reflect the tightness of intercellular junctions between epithelial cells, and can be 
used as an indicator of epithelial viability for mucosal permeation experiments37, 53. A decrease 
in TEER measurements is also an indication of the opening of tight junctions between adjacent 
epithelial cells, which indicates an enhancement of the paracellular permeability across the 
epithelial cell layer38. However, the reported values in the limited studies on porcine buccal 
mucosa permeation varying widely (144 ± 12 to 950 ± 392 Ω/cm2),  with standardization for this 
type of experiment still needing to be developed37,54.  
 
The TEER values across the buccal mucosa prior to the permeation experiment (control) in this 
study was found to be between 322 ± 17 to 458 ± 21 Ω /cm2 (Table 3), which compare favorably 
with the range reported for such studies in the literature37,54. TEER values at time zero (control) 
were used as 100%. After six hours of permeation, these values decreased to a range of 5.70 ± 
1.4 to 11.4 ± 2.8 % (Figure 2) from the initial values recorded. These reductions in the TEER 




values are indicative of the opening/widening of intercellular junctions, which facilitates the 
permeation of SQV across the buccal mucosa. As there was a decrease in all samples tested 
(Figure 2 and Table 3), this indicates that SQV utilizes the paracellular route of transport across 
the buccal mucosa. It was observed that the sample with the greatest decrease in TEER values 
after the permeation, the 15 hour sample, also displayed the greatest enhancement ratio of 
2.61. Two hours after the replacement of the drug solution from the donor chamber with fresh 
PBS, the TEER values increased within a range of 319 ± 18 to 435 ± 23 Ω /cm2 from the values 
measured after permeation (Table 3). There was also a difference of only 3.04 ± 0.8 to 6.73 ± 
1.9 % between initial TEER values measured and those two hours post permeation (Figure 2). 
These values are a reflection of the recovery of the mucosa post drug treatment and signified a 
return towards the initial measured integrity. The TEER values obtained in this study appear to 
be within the reported range, and the overall percentage change also indicates that mucosal 
integrity was not irreversibly affected37, 55. The results of the TEER study correlated with the 
histomorphological studies (Section 3.3), which further confirmed that integrity and viability of 
the tissue was maintained. 
 
Table 3: TEER measurements across the buccal mucosa after permeation with milled SQV 
samples 




6 hr permeation 
(Ω/cm2) 
*% reduction in 
TEER after 6hr 
permeation 
2 hrs post 
permeation (Ω/cm2) 
1 458 ± 21 424 ± 24 7.42 % 435 ± 23 
3 394 ± 12 368 ± 21 6.59 % 382 ± 9 
15 386 ± 22 342 ± 27 11.39 % 360 ± 27 
30 332 ± 17 313 ± 21 5.72 % 319 ± 18 




* % change compared to control (0 hrs) 
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Figure 2: % change in TEER values after permeation with milled SQV samples. 
This study has demonstrated that high energy ball milling is an effective strategy for enhancing 
SQV permeation across the buccal mucosa, and that the enhanced permeability is due to a 
contribution of various factors such as solubility, particle size, surface area, and the formation of 
solid dispersions.  
3.2 Effects of permeation enhancers on SQV permeability 
Low mucosal permeability has been reported as one of the disadvantages associated with the 
buccal route of drug administration. The lipid matrix of the extracellular spaces plays a role in 




the barrier function, particularly if the permeating compounds have higher molecular 
weights12,56, and paracellular transport of macromolecules are restricted by tight junctions or 
similar interconnections that exist between cells5,7,57,58. To help alleviate this, 
permeation/penetration enhancers have been used to promote absorption of a drug across the 
buccal mucosa by decreasing its barrier properties, thereby delivering therapeutically relevant 
amounts into the systemic circulation. SQV could show increased permeability across the 
buccal mucosa if it were coupled with permeation enhancers. High energy ball milling of SQV 
displayed enhanced permeability of SQV (Figure 1 and Table 2), and the increased permeability 
to enhancement the ratio’s obtained for SQV using commonly employed chemical enhancers in 
the literature was investigated.  
 
Buccal permeation enhancers from the different classes (surfactants, fatty acids, inclusion 
complexes and chelators) were used as permeation enhancers for SQV. EDTA, SLS, ß-
cyclodextrin and PEG were chosen as they have been reported to have significant 
enhancement potential6, 35. The respective enhancers were added to the donor chamber at 
0.5% w/v. This concentration was chosen as it has been widely used in previous studies that 
incorporated different enhancers within their donor solutions for permeability studies19, 35,  51. The 
results of this study showed that the permeability of SQV was increased in the presence of all 
the enhancers (Figure 3 and Table 4), these increases being statistically significant (p < 0.05). 
The addition of SLS displayed the greatest increase in steady state flux value, which increased 
from 3.99 ± 0.11 µg/cm2hr  to 6.99 ± 0.7 µg/cm2 with an enhancement ratio of 1.75 (Table 4), 
which was statistically significant. These enhancement ratios are in keeping with those achieved 
by these classes of enhancers and regarded as effective in the literature6, 35. Changes in the 
steady state flux values and permeability coefficient could have resulted from the enhancers 
increasing the transport pathways through the buccal mucosa as described in the introduction. 




The greatest enhancement obtained using the chemical enhancers (ER = 1.75) was lower than 
the lowest enhancement ratio obtained by milling SQV ie. 30 hour milled with an ER of 1.8. The 
flux values obtained in this study are similar or greater than flux values reported for other ARV 
drugs, as well those identified as having potential for buccal delivery e.g. Didanosine, Tenofovir, 
Ondansetron HCl, Risperidone and Decitabine19, 35, 40-42. As the enhancement ratios obtained 
using the milled samples are comparable or greater than those obtained when using chemical 
methods for permeation enhancement, as previously described, these results confirm that at an 
equivalent concentration ball milling of SQV is more effective for permeability enhancement than 
the addition of EDTA, SLS, ß-cyclodextrin and PEG at 0.5% w/v. 
 






















































Figure 3: Effect of enhancers on the cumulative amount of unmilled SQV permeated across the 
buccal mucosa. 
Table 4: Effect of permeation enhancers on buccal permeability properties  




unmilled SQV 3.99 ± 1.15 19.95 ± 0.57 
 
unmilled SQV + 0.5%ßCD *6.35 ± 2.37 31.75 ± 11.91 1.59 
unmilled SQV + 0.5%EDTA *6.79 ± 0.9 33.99 ± 4.50 1.7 
unmilled SQV + 0.5%PEG 4.20 ± 1.52 21.0 ± 7.61 1.05 
unmilled SQV + 0.5%SLS *6.99 ± 0.7 34.95 ± 3.54 1.75 
* Indicates significant difference i.e p < 0.05 (all values compared to unmilled SQV) 
3.3 Histomorphological evaluations 
The effect of the ARV drug SQV in its unmilled and milled form on the buccal mucosa was 
investigated histomorphologically to determine any deleterious effects of SQV on the cells of the 
buccal mucosa, with Light Microscopy (LM) and Transmission Electron Microscopy (TEM) being 
used to determine any loss of tissue viability35, 37. The one hour and 15 hour milled samples 
were chosen as they displayed the greatest increase in SQV permeability. Assessing the impact 
of the drug on the histomorphology of the tissue included toxic effects upon exposure. It must be 
noted the barrier function of the stratified epithelium lends itself to ‘rebound’ effect after 
prolonged exposure to a drug, which was not assessed in this study. However, adequate 
information can be obtained from LM and TEM images to determine whether the tissue suffered 
permanent/irreversible damage after exposure to the drug treatment. 
  
The buccal mucosa is multilayered, consisting of a changing morphology from base to apex, 
originating at the basal lamina, which it superficial to the lamina propria. The basal lamina is 




lined by regenerative basal cuboidal cells that stain very darkly in LM preparations, depicting its 
highly mitotic activity37. As the cells transgress closer to the surface, they become flattened and 
more closely packed, with less distinguishable intercellular spaces, which mainly present 
between cells closer to the basement membrane in TEM preparations. Any molecule that enters 
the circulation via the buccal mucosa must first traverse through these layers before it enters the 
circulation present in the lamina propria. 
 
The control images (Figure 4b) of the H&E preparations closely resembled the description given 
above, indicating that the animal tissue used in the study was normal and healthy. The H&E 
micrographs of the treated samples were similar to that of the controls (Figure 4c and 4d), with 
cells showing normal morphology and darkly stained basal cells, depicting no decrease in the 
activity of these regenerative cells compared to their counterparts in the control image. There 
were also no observable cellular distortions and the basal lamina remained intact, preserving its 
supportive role and barrier function. Any damage observed to the superficial layers, caused by 
the drug treatment of the mucosa, should not be considered permanent, as the buccal mucosa 
has a high recovery rate14. However, no such observations were made in this study, the data 
from the H&E preparations suggesting that SQV permeation for a duration of six hours has no 
permanent effects on the buccal mucosa. 












Figure 4: Photomicrographs of the control and the treated buccal mucosal selections for light 
microscopy (LM) stained with H&E ; (× 10) a control/untreated, b treated with unmilld SQV, c 











TEM allows for a more in depth analysis of the tissue sample at a cellular level, and was 
therefore used to confirm the observations made with the H&E preparations, and the condition 
of the cellular components needed for the proper functionality of individual cells was assessed. 
Although limited, the TEM micrographs may provide clues to possible modes of transport across 
the cell, as the intercellular spaces between neighbouring cells was evaluated, being used as a 
route of paracelluar transport across the mucosa. The conditions of the tight junctions that link 
these neighboring cells together were simultaneously observed, with their damage possibly 
leading to the tissue losing its ‘rebound’ affect. A permeant is able to use either the transcellular, 
paracellular or both the routes simultaneously to transgress through the multiple layers of the 
buccal epithelium14. The physicochemical properties of a drug can also influence the 
mechanisms and pathway of transport across the buccal mucosa. The paracellular mode may 
be one of the mechanisms that SQV uses to permeate across the mucosa, as shown by the 
increased intercellular spaces between the cells in the treated samples (Figure 5b and 5c) when 
compared to the control (figure 5a). This therefore suggests that although SQV is lipophilic and 
would most likely use the transcellular route of transport, it also utilizes the paracellular route. Its 
use of the paracellular route as indicated in these TEM images correlates with the TEER values. 
It was observed that the samples with the greatest extent of TEER reduction after the 
permeation (Table 3), i.e. 1 and 15 hour samples, also displayed the greatest permeation 
enhancement ratio of 2.58 and 2.61 respectively (Table 2). These findings therefore are in 
agreement with the TEM results which describes the larger intercellular spaces observed for 
these samples.   
The TEM micrographs of the control displayed all the characteristics of healthy cells (figure 5a), 
and while the treated samples (figure 5b and 5c) also appeared to have no cellular damage, 
mild convolutions in the nuclear membranes (figure 5d) were observed.  Although these may not 




necessarily be deleterious to the cells, as no signs of necrosis, such as destruction of the 
nuclear membrane and nucleus, or damage to the cellular membrane were observed. An 
increase in the size of the intercellular spaces in the treated samples (figure 5b and 5c) was 
observed, these could have aided the transport of the drug via the paracellular route across the 
mucosa. The TEM Micrographs also displayed intact tight junctions in both the control as well as 
the treated samples (figure 5e and 5f respectively), which indicated that although the size of the 
intercellular spaces have been increased in the treated samples, they will not lead to permanent 












































Figure 5: Electromicrographs of the control and the treated buccal mucosal selections for 
transmission electron microscopy (TEM ) : a control/untreated  (× 4000), b 1 hr milled SQV (× 
2500), c 15 hr milled (× 6000), d  unmilled SQV showing nuclear distortions (× 5000), e 








LM and TEM images supported the assessment of no irreversible tissue damage to the mucosa 
after exposure to the drug treatment for six hours. TEM assessments further provided a possible 
mode of transport for SQV across the mucosa, and both LM and TEM observations provided 
reasons to believe that any changes brought about by the drug treatment would be temporary. 
These studies therefore confirmed that exposure to SQV did not have any adverse effects on 
the buccal mucosa. 
 
4. CONCLUSIONS 
Enhancing permeation across the buccal mucosa is a major challenge and therefore an area of 
great interest in the literature, with electrical mechanisms and chemical enhancers being the 
most widely studied approaches. In light of the need for studies to widen the pool of available 
strategies to increase buccal permeation, this study investigated the buccal delivery potential of 
an ARV drug, SQV, and the effect of ball milling as a strategy to enhance permeation across the 
buccal mucosa compared to commonly used chemical permeation enhancers. The results 
indicated that both unmilled and milled samples were able to permeate the buccal mucosa, with 
the optimal sample being the 15 hour milled displaying the greatest permeability with an 
enhancement ratio of 2.61. This enhanced permeability of the milled SQV samples was 
attributed to a contribution of various factors such as solubility, particle size, surface area, 
crystallinity, morphology and the formation of solid dispersions. All of the permeation enhancers 
studied were also able to increase the permeability of SQV across the buccal mucosa, with SLS 
achieving the greatest enhancement ratio of 1.75. However, all of the milled samples displayed 
greater permeability than the best permeation enhancer SLS, and are therefore more effective 
as a means of permeation enhancement. Histological investigations revealed no significant loss 
in cellular integrity for mucosa treated with either unmilled or milled SQV samples. The 
presence of larger intercellular spaces in the treated tissue suggests that SQV also uses the 




paracellular route of transport in combination with the transcellular route across the mucosa. 
Therefore high energy ball milling of SQV is an effective approach of increasing buccal 
permeability when formulating SQV for a buccal delivery system, when compared to 
incorporating the enhancers studied at 0.5% w/v into the delivery system for this purpose. SQV 
milled samples may therefore be considered as having the potential for improving HIV/AIDS 
drug therapy when administered via the buccal mucosa instead of the oral route. 
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Buccal delivery of drugs, including ARVs, can overcome several limitations associated with the 
oral route thereby improving drug therapy and patient outcomes. Due to the small mucosal 
surface area and poor membrane permeability, strategies to improve drug permeation across 
the buccal mucosa are a major research area. The aims of this study were therefore: 1) To 
identify and compare the buccal permeability potential of tenofovir (TNF) and didanosine (ddI). 
2) To identify the buccal permeation effects of potential multifunctional excipients ie. 
carboxymethylcellulose (CMC), sodium alginate (SA), polyacrylic acid (PAA) and polyethylene 
glycol (PEG) for TNF and ddI, and 3) To identify the buccal permeation potential of saquinavir 
(SQV) and assess the effect of high-energy ball milling on its permeability. The following 
conclusions can be drawn from the various investigations in this study. 
 
 Both TNF and ddI were able to permeate the buccal mucosa in a concentration-
dependent manner with ddI having a higher permeability (Flux = 181.62 ± 23.62 
µg/cm2h) as compared to TNF (Flux = 102.10 ± 19.80 µg/cm2h). The permeation of 
these drugs in the absence of enhancers was attributed to passive diffusion via the 
paracellular route with transcellular route being an additional possibility for ddI. 
 
 Polymeric excipients previously reported to have mucoadhesive and controlled release 
properties were shown in this study to additionally display buccal drug permeation 
enhancing effects. The addition of PAA, SA, CMC and PEG increased the permeability 
of TNF whilst only PEG was able to increase the permeability of ddI.  Furthermore PEG 




was identified as the optimal permeation enhancer for TNF and ddI. The effect of these 
polymeric excipients appeared to be dependent on their ionic charges as well as that of 
the respective drugs. 
 
 Histological investigations revealed no significant loss in cellular integrity for mucosa 
treated with either TNF or ddI, alone or when coupled with PEG as an enhancer. The 
differences in histomorphological changes in response to TNF and ddI alone could 
support the greater permeation observed with ddI. The histological findings proved 
useful in assessing the effects on mucosal integrity and provided insight into permeation 
pathways across the mucosa. 
 
 Selective polymeric excipients therefore provide an effective means to increase the 
penetration of ddI and TNF. Their previously reported mucoadhesive and controlled 
release properties coupled with their permeation enhancing effects shown in this study 
highlight their potential use as multifunctional excipients for the design of buccal drug 
delivery systems. 
 
 Unmilled SQV was able to permeate through the buccal mucosa with a flux of 3.99 ± 
0.11 µg/cm2h. Ball milling of SQV at all the time periods led to its increase in 
permeability with optimal enhancement obtained at 15 hrs with an enhancement ratio of 
2.61. The enhanced permeability of the milled SQV samples was attributed to a 
contribution of various factors such as solubility, particle size, surface area, crystallinity, 
morphology and the formation of solid dispersions. 
 




 Common chemical permeation enhancers ie. PAA, SA, CMC and PEG were also able to 
increase the permeability of unmilled SQV across the buccal mucosa, with SLS 
achieving the greatest enhancement ratio of 1.75. However, ball milling of SQV without 
any chemical permeation enhancers led to a greater enhancement ratio (2.61) as 
compared to that of the best permeation enhancer SLS at 0.5 %w/v with unmilled SQV 
(1.75). Ball milling of SQV therefore proved to be an effective strategy for permeation 
enhancement of SQV. 
 
 Histological investigations revealed no significant loss in cellular integrity for mucosa 
treated with either unmilled or milled SQV samples. The presence of larger intercellular 
spaces in the treated tissue suggests that SQV also uses the paracellular route of 
transport in combination with the transcellular route across the mucosa. 
 
 High energy ball milling of SQV is therefore an effective approach for increasing buccal 
permeability of SQV as compared to the conventional approach of incorporating 
common chemical enhancers at 0.5 %w/v with unmilled SQV. These findings offer the 
possibility of also obviating the need for additionally adding chemical permeation 
enhancers into a buccal drug delivery system.  
 
This study has identified the buccal permeability properties of three ARV drugs TNF, ddI and 
SQV. It also identified new chemical permeation enhancers that can provide multifunctional 
properties in a buccal drug delivery system. Furthermore, ball milling an ARV drug is an 
additional strategy for enhancing permeation across the buccal mucosa. These findings will 
provide formulation scientists with effective strategies for optimizing the development of novel 
ARV buccal delivery systems for improving the treatment of patients with HIV and AIDS. Buccal 




drug delivery is currently acknowledged as one of the delivery mechanisms significant for 
improving therapeutic outcomes of current drugs. This study has therefore made a significant 
contribution to addressing a challenge within this important field in the pharmaceutical sciences. 
 
 
5.2 RECOMMENDATIONS FOR FUTURE WORK 
  
Modifying the route of administration of an existing drug, who’s biological and physicochemical 
characteristics are well understood, is recognised as an alternative cost effective approach for 
improving therapeutic outcomes as compared to only developing new chemical entities. In light 
of this, significant focus is placed on improving the delivery of currently marketed drugs. This 
study has therefore addressed important challenges in this field prior to formulation of these 
ARVs into a buccal drug delivery system. In this regard, further studies are essential to optimize 
the efficient and convenient delivery of these ARVs via the buccal route of administration. 
Future work should therefore be in the direction of: 
 
 Performing further transport and mechanistic studies, on TNF, ddI and SQV, such as 
fluorescent and/or laser confocal fluorescent microscopy. These techniques are able to 
characterize the exact route and also to establish the most preferred route of transport 
across the mucosa by the drug. These findings will further confirm the assertions made 
from the light and transmission electron micrographs in this study and will provide further 
insight for formulation scientists to consider when developing new strategies to enhance 
the permeation of drugs across the buccal mucosa. 
 
 Exploring the use of novel derivatives of existing chemical enhancers as buccal 
permeation enhancers for these model ARV drugs. Recent literature shows an emerging 
trend of synthesising novel derivatives of well known and safe chemical permeation 




enhancers that are superior to their parent compound. Synthesising and indentifying 
buccal permeation enhancing potential of new derivatives such as fatty acids will 
increase the number of approaches available to enhance the permeation of drugs across 
the buccal mucosa. 
 Designing and manufacturing of delivery systems (buccal films, buccal patches etc.) for 
the delivery of TNF, ddI and SQV with optimal formulation excipients such as polymers 
and enhancers being taken into consideration to ensure adequate release and delivery 
of therapeutically relevant doses into the systemic circulation.  
 
 Performing in-depth characterization studies on the performance of the prepared buccal 
delivery systems such as drug content, dissolution studies as well as mechanical and 
mucoadhesive assessments to optimize the formulation and obtain a mechanistic 
understanding of the delivery system.  
 
 Performing in vivo evaluations of the buccal delivery system in a suitable animal model 
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